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Abstract 
Brain metastases are common intracranial tumours which cause considerable morbidity and 
mortality. There are a variety of treatment modalities for brain metastases, including surgery, 
radiation and chemotherapy. There is, however, disagreement about the best combination of 
these therapies and prognostic scoring systems are not individualised. MRI is frequently 
obtained in the course of diagnosing these tumours and advanced MRI sequences, in 
particular diffusion MRI, which measures white matter disruption, may provide useful 
prognostic information which is patient and tumour specific. Finally, the interface between 
the brain metastasis and the surrounding brain has been poorly investigated compared to 
intrinsic brain tumours such as glioma, and may be a rich source of therapeutic targets and 
biomarkers. This thesis therefore aimed to derive biological and radiological markers of local 
brain metastasis invasion, intracranial progression and survival which may be used in clinical 
practice, whilst deepening scientific understanding of the brain-brain metastasis interface.  
Expression of the metastasis-inducing protein S100A4 was identified as a possible predictor 
of metastasis recurrence post operatively and OPN as a possible marker of radiation response. 
Using diffusion MRI, the change in the change in the apparent diffusion coefficient (ADC) 
across the brain-brain metastasis boundary was found to be a reliable, repeatable measure on 
clinically obtained scans and independently associated with overall survival for operated 
brain metastases. Finally, using combined image-guided neurosurgical samples and diffusion 
tensor imaging, we have shown that the FA in the peritumoural region is a surrogate marker 
of the density of T cell infiltration there and that both increased CD3+ T cell infiltration and 
reduced FA (corresponding to more white matter tract disruption) are associated with 
prolonged overall survival after macroscopic resection.  
These studies highlight the importance of studying the brain-brain metastasis interface both 
radiologically and biologically whilst offering truly novel avenues for further study in the 
field, including imaging, tissue biomarkers and potential therapeutic targets.   
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Chapter 1: An introduction to cerebral metastases 
 
 
Cerebral metastases are secondary brain tumours which have spread from an 
extracranial, primary cancer. Herein - as with the wider medical literature – “cancer” 
is taken to mean a solid organ primary cancer, thus excluding haematological 
malignancy such as lymphoma. The term brain metastasis is used interchangeably 
with cerebral metastasis. 
  
1.1 Epidemiology 
 
Cerebral metastases are common intracranial tumours, but estimates of incidence are 
inconsistent due to the variety of different sources of information. In the general 
population, studies from Europe and North America consistently find incidence rates 
of between 7 and 14 per 100,000 (Fox et al., 2011). By comparison, recent figures 
for other common brain tumours are 4.6 per 100,000 for glioblastoma (the most 
common primary malignant brain tumour) and 7.6 per 100,000 for meningioma (a 
generally benign tumour of the brain envelope or meninges) (Brodbelt et al., 2015, 
Ostrom et al., 2014). This population data encompasses the risks of cancer, however, 
since one cannot develop a brain metastasis without having a primary cancer, known 
or unknown (Barnholtz-Sloan et al., 2004). Hence studies in the “at risk” population 
of patients with a known solid organ cancer may be more useful. In such groups, the 
incidence of brain metastasis has been reported as high as 1 in 4 (25%) at post 
mortem (Posner and Chernik, 1978). Such rates are not seen in clinical practice, 
however, and in fact around 1 in 20 (6%) of newly diagnosed patients with cancer in 
a given year would be expected to develop a brain metastasis (Davis et al., 2012). 
This means the longer patients survive with their primary cancer, the greater the 
incidence of brain metastases should be; accordingly, improved imaging availability 
and better systemic treatments have coincided with increased numbers of these 
tumours, as Figure 1.1 illustrates, and an increase in their scientific investigation 
(Owonikoko et al., 2014).  
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Figure 1.1: Bar chart showing the estimated  lifetime  metastases  of  the  brain  for  selected 
primary cancer sites, by individual year of diagnosis in the United States, 2003– 2007 (Davis 
et al., 2012). 
 
 
1.2 Aetiology 
 
In keeping with Paget’s seed and soil hypothesis of cancer spread (Paget, 1889), it 
has always been known that particular cancers (seed) have a higher than expected 
incidence of metastasis to the brain (soil). The most common sites of primary cancer 
for brain metastases are shown in Figure 1.2  (based on raw data from (Nussbaum et 
al., 1996)).  
 
The processes by which tumour cells escape their primary site of origin, enter the 
circulation, survive there and finally seek out and populate a new site is extensively 
studied and referred to as the metastatic cascade (Winkler, 2015, Beasley and Toms, 
2011, Svokos et al., 2014, Preusser et al., 2012, Rahmathulla et al., 2012). A number 
of steps comprise this cascade including: 
 Proliferation and cellular heterogeneity in the primary site 
 Epithelial-mesenchymal transition 
 Interaction with tumour stroma 
 Local invasion  
 Migration 
 Enter and exit the circulatory system 
 Colonisation of the host site 
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Figure 1.2: Summary of primary solid organ cancers causing metastasis to brain reproduced 
as a pie chart from an original series of 729 cases gathered over a 20 year period 
(Nussbaum et al., 1996). The exploded slices show that three sites – lung, breast and skin – 
account for the majority of cases. NSCLC = non-small cell lung cancer. SCLC = small cell 
lung cancer, GI = gastrointestinal tract. 
 
Specific to brain metastases is the requirement to cross the blood brain barrier and 
survive in the unique microenvironment of the central nervous system. This process 
is now increasingly thought to rely on cell adhesion molecules (CAM) (Soto et al., 
2014) with a process similar to inflammatory cell “rolling” adhesion and migration. 
Once across the blood brain barrier, metastatic cells occupy a niche in the 
perivascular region and either spread along this plane as described in Section 1.3.2 
Microscopic pathology or induce angiogenesis to enable their continued growth 
(Kienast et al., 2010).  
  
 
1.3 Pathology 
 
1.3.1 Macroscopic 
Brain metastases occur at areas of high cerebral blood flow because they derive from 
tumour cells carried in the circulation from the primary site. This explains historic 
observations that some 80% are distributed in the hemispheres, 15% in the 
cerebellum and 5% in the brainstem/basal ganglia and this has not been disproven by 
newer imaging modalities (Delattre et al., 1988, Fink and Fink, 2013). These tumours 
appear as solid, firm lesions at the grey-white matter interface (where narrow, 
branching blood vessels lead to tumour cell arrest and adhesion) with occasional 
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haemorrhage, especially in melanoma, renal cell and thyroid cancer types. They tend 
to be surrounded by intense vasogenic oedema. Around 1/3 are solitary (Norden et 
al., 2005) and the remainder oligo- or polymetastatic (the cut-off between these two 
arbitrarily taken to be 4 or 5 distinct lesions depending on the study). Metastases vary 
in size from what is termed “unmeasurable disease” of <5mm diameter to very large 
tumours and at present response is assessed using diameter, as if tumours were a 
perfect sphere (Lin et al., 2015). Whilst volume may be a useful measure of response 
in future, it is likely the total volume of disease (i.e. all the lesions in the brain) is 
more important (Kondziolka et al., 2014), although harder to measure in real time. 
 
 
1.3.2 Microscopic: the brain-brain metastasis interface 
 
Microscopically brain metastases tend to show characteristics of the primary cancer 
including architecture, such as mucin secreting glands. However, in cases of poorly 
differentiated metastases, staining for glial markers such as glial fibrillary acidic 
protein (GFAP), OLIG2, and SOX2 may be performed to help distinguish from 
glioma (Pekmezci and Perry, 2013). Historically, metastases were always said to be 
clearly delineated from the surrounding brain and the microscopic presence of a 
pseudocapsule - illustrated in Figure 1.3 – may explain the often recounted 
neurosurgical description that they shell out like a pea from a pod.  
 
 
Figure 1.3: Photomicrographs of a renal cell carcinoma metastasis from the Walton 
Research Tissue Bank. Panel A. GFAP stain highlights the compressed glial component of 
the pseudocapsule around the resected tumour. 12.5x magnification, scale bar = 1mm. This 
is seen macroscopically by the operating neurosurgeon as a plane between tumour and 
brain. Panel B. shows this pseudocapsule at high power (arrowheads) with H&E staining, 
200x magnification, scale bar = 50µm. 
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Recent evidence accumulated from post mortem and in vivo studies, however, has 
contradicted this understanding and the microscopic boundary between metastases 
and brain may be more complex than previously thought, with implications for both 
treatment and prognosis. A post mortem study of 57 cases within the Austrian brain 
tumour bank showed diffuse infiltration in around one third of cases with no 
association of growth pattern with a particular primary (Berghoff et al., 2013b). The 
remainder showed either well demarcated margins or co-opting of existing vessels in 
the peritumoural region, a well described growth pattern that has been observed in 
animal models (Carbonell et al., 2009) and in human studies (Pekmezci and Perry, 
2013). A second autopsy study of 45 patients suggested fewer than half of metastases 
show a clear demarcation from brain, with 70% of lung cancer cases, particularly 
small cell lung cancers, showing infiltrative growth (Baumert et al., 2006). This 
association with lung cancer is well established with 26 of 66 cases of metastatic 
anaplastic small cell carcinoma showing poorly defined borders in an in vivo study, 
what the authors describe as a pseudogliomatous pattern  (Neves et al., 2001). 
Finally, this infiltrative growth pattern has recently been shown to be associated with 
a worse prognosis compared to the well demarcated cases in a prospective series 
(Siam et al., 2015) receiving adjuvant treatments.  
 
1.4  Symptoms and presentations 
 
Common signs and symptoms follow from the pathological description above: 
almost half of patients present with seizures due to the location of metastases at the 
grey-white matter boundary and the remainder with headache and neurological 
compromise due to vasogenic oedema and compression of deep white matter tracts 
(Taillibert and Delattre, 2005). Synchronous presentation of metastases refers to 
patients with no previously identified primary cancer. Patients with no signs or 
symptoms of brain metastases are increasingly being screened by their oncologist; up 
to 15% of breast (Miller et al., 2003) and 40% of non-small cell lung cancer brain 
metastases may be asymptomatic yet detectable by conventional radiological studies 
(Ohana et al., 2014).  
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1.5 Investigation  
 
1.5.1 Assessment  
Patients are assessed with a thorough history - including of any prior cancer - 
followed by clinical examination, paying attention to neurological deficits and 
dysfunction as well as any extracranial signs of the primary tumour. Imaging is then 
used to assess both the brain and the extracranial disease. The primary cancer may be 
detected and staged by whole body CT scan (chest, abdomen and pelvis) or where 
available PET-CT. 
 
1.5.2 The role of MRI 
MRI is crucial in making the diagnosis, determining the best course of management, 
monitoring response to therapy and increasingly in trying to predict prognosis. 
Rather than reviewing each individual technique and its applications separately, as 
has been done elsewhere, the different clinical problems encountered in brain 
metastases are presented and the relevant MRI techniques which can be applied in 
each scenario addressed (Zakaria et al., 2014b).  
1.5.2.1 How many brain metastases are present? 
Accurately identifying the number, location and size of brain metastases is important 
to determine which interventions are most appropriate for that patient and multiple 
scoring systems which stratify outcomes of therapies take into account the number of 
lesions, for example, the Recursive Partitioning Analysis or RPA classification 
(Jenkinson et al., 2011, Nieder et al., 2009, Siu et al., 2011, Gaspar et al., 1997). 
With respect to detection, localisation and quantification, contrast enhanced MR has 
been widely demonstrated to be superior to both enhanced CT and non-enhanced MR 
(Yokoi et al., 1999, Schellinger et al., 1999, Kruger et al., 2011, Davis et al., 1991). 
The recommended gadolinium dose in this context is 0.1 mmol/kg and whilst double 
or triple dose administration has been suggested to increase the detection of small 
lesions, this causes increased false positives and a higher risk of nephrogenic 
systemic fibrosis, therefore it remains an “off label” use (Yuh et al., 1995, Sze et al., 
1998, Schneider et al., 2001).  
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Could novel sequences and agents therefore increase detection without escalating the 
contrast dose? Different gadolinium based agents, all of which may have slightly 
differing relaxivity profiles, have been variously compared and these studies are 
summarised elsewhere, but at present gadobutrol appears to identify the greatest 
number of lesions with the greatest contrast to noise ratio, whilst having a lower risk 
of nephrogenic systemic fibrosis, along with the other “cyclic” structured gadolinium 
based agents (Anzalone et al., 2013). MR sequences are developing rapidly, but are 
not always explicitly evaluated against existing protocols. Magnetisation saturation 
transfer (MT) imaging has been directly compared to gradient echo T1 sequences 
and its addition reduced by half the standard dose of contrast needed for detection 
leading some to advocate it over ever increasing contrast doses (Ginsberg and Lang, 
1998, Haba et al., 2001). More recently, 3D T1 weighted “spoiled gradient echo” 
(SPGR)  and T2 weighted post contrast FLAIR sequences have been shown to detect 
sub-millimetre (<3mm) abnormalities and more sensitively assess leptomeningeal 
disease (Chen et al., 2012a, Kakeda et al., 2007).  
 
Figure 1.4: A patient known to have melanoma presents with a first seizure and (A) 
unenhanced CT brain (32-slice scanner, 10 mm slices) taken in the emergency department 
shows an abnormality in the left frontal lobe with surrounding oedema – they were referred 
for possible neurosurgical intervention. (B) T1 weighted MRI at 1.5 T with single dose (0.1 
mmol/kg) gadolinium contrast detects this lesion but also delineates it further, allowing 
volume to be assessed accurately and in addition highlights two further areas of abnormality. 
After staging of the systemic disease and discussion with oncologists and surgeons, the 
patient was therefore treated with stereotactic radiosurgery to all three areas. 
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The spatial resolution of the acquisition differs depending on the indication for the 
scan and this has important implications for detection and management which need 
to be kept in mind. For example, if a treatment is decided upon with the 
multidisciplinary team and the patient but then a surgical or SRS “planning” scan of 
higher spatial resolution is obtained, the latter  will be more sensitive for detection of 
metastases than a conventional diagnostic scan and multiple, previously unseen 
lesions may be identified which render that treatment inappropriate (Nagai et al., 
2010). 
 
1.5.2.2 Is this solitary lesion a metastasis, an abscess or a high grade glioma? 
A patient presenting with no known primary cancer and a solitary ring enhancing 
brain lesion may be suspected to have a brain metastasis, a primary cerebral tumour 
such as glioblastoma or a cerebral abscess, and despite careful history and exam, 
misdiagnoses may still occur (Brodbelt, 2012). Distinguishing abscess from tumour 
is perhaps the most clinically relevant question and in this regard diffusion-weighted 
MRI (DWI) has been most useful. Diffusion-weighted images detect free water 
movement and allow a surrogate of diffusion to be calculated for each voxel to 
generate apparent diffusion coefficient (ADC) maps. A large number of 
observational studies have shown that for a solitary cystic or necrotic contrast 
enhancing lesion, restriction of diffusion on pre-operative MRI is predictive of 
abscess (Desprechins et al., 1999, Ebisu et al., 1996, Krabbe et al., 1997, Kim et al., 
1998). Modifications to imaging protocols have increased sensitivity, including 
detection of early capsule formation during abscess development and even prediction 
of cellularity of abscesses at higher b-values and field strengths (Tomar et al., 2011, 
Fertikh et al., 2007). However, there are persistent cautions that some metastasis may 
show restricted diffusion and mimic the appearances of abscesses, for example two 
different studies have reported this for non-small cell lung carcinoma metastases and 
others have described it for lymphoma (Stadnik et al., 2001, Holtas et al., 2000, 
Duygulu et al., 2010, Hayashida et al., 2006). 
Distinguishing metastases from high grade glioma has proven more difficult using 
DWI, although in theory the region of vasogenic oedema around metastases should 
show greater free diffusion than the more cellular, infiltrated region around a high 
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grade glioma. Studies have varied in their cut-off for distinguishing the two 
pathologies as well as the methodology of how to take the reading (does one use the 
lowest ADC value, the mean of multiple measurements and which areas should one 
sample in the peritumoural region?) and there is no agreement about reliability 
(Bulakbasi et al., 2005, Chiang et al., 2004, Lee et al., 2011, Wang et al., 2009, Calli 
et al., 2006). Diffusion tensor imaging (DTI) is an enhancement of DWI with more 
diffusion gradients and directions used during acquisition. This allows more 
advanced metrics than just the average diffusion coefficient to be calculated and 
disruption of white matter tracts to be visualised. Again, the theory that high grade 
glioma is an invasive tumour which infiltrates white matter tracts whereas a 
metastasis deforms them is supported, but not consistently repeated by studies 
examining DTI metrics such as fractional anisotropy and mean diffusivity which may 
be superior to ADC alone (Byrnes et al., 2011, Price and Gillard, 2011, Tsuchiya et 
al., 2005). 
 
Further advanced techniques have therefore been combined with diffusion imaging 
in this context to try and increase sensitivity, most commonly MR spectroscopy 
(Bulakbasi et al., 2003). Single and multivoxel magnetic resonance spectroscopy 
(MRS) provides information about the metabolic profile of specific regions in and 
around a lesion (Pinker et al., 2012, van der Graaf, 2010). Proton MRS has 
previously shown discriminatory power between high grade glioma and metastasis 
by measurement of the choline/NAA ratio (Server et al., 2010, Wong et al., 2010). 
Novel spectroscopic markers continue to be investigated, including lipid and 
macromolecule concentrations by proton MRS (Crisi et al., 2013) and phosphate 
metabolites by 31P MRS (Ha et al., 2013).   
 
Further information on physiological activity can be gathered by combining with MR 
perfusion studies. MRI perfusion permits the generation of maps of relative cerebral 
blood flow (rCBF) and volume (rCBV) which are measures of vascularity. High 
grade glioma pathologically shows neovascularisation and infiltration of surrounding 
brain, hence the peritumoural rCBV is higher than for a metastasis (Blasel et al., 
2010, Law et al., 2002). Using the same dataset and different post processing 
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techniques, diffusion susceptibility contrast or DSC MRI allows prediction of tissue 
permeability, a measure of blood-brain barrier disruption and this accordingly 
increases around a metastasis, where there is increased capillary permeability and 
therefore vasogenic oedema (Lacerda and Law, 2009, Thompson et al., 2010).  
 
Figure 1.5: An elderly patient was referred with hemiparesis and suspected to have a stroke. 
MRI demonstrated a lesion in the left hemisphere which on (A) T1 weighted axial image post 
gadolinium at 1.5 T is shown to have a solid and ring enhancing portion. (B) The associated 
ADC map shows considerably reduced diffusion at the site of the solid portion of the lesion 
with increased diffusion due to vasogenic oedema in the white matter surrounding the mass. 
(C) Single voxel proton MRS of the lesion yields an abnormal spectrum with a large lipid and 
lactate peak, reduced NAA, reduced Cr and slightly elevated Cho. This pointed to a 
metastasis, glioma or lymphoma as opposed to an abscess. There was time to optimise the 
patient for surgery and begin steroid treatment before the lesion was resected and confirmed 
to be a renal cell carcinoma. 
Summary: Multimodal MR used singly or in combination has improved our ability to 
distinguish metastases from primary cerebral tumours or abscesses. Despite the 
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application of these advanced MR techniques of diffusion, perfusion and 
spectroscopy to solve this clinical problem (Server et al., 2011) it remains a fact that 
for accessible, larger lesions surgery is often undertaken and tissue diagnosis 
obtained regardless in order to move forward treatment. The role and evidence for 
MRI in surgical planning is therefore the next area to consider. 
 
1.5.2.3 Surgical planning 
Image guided surgery allows the surgeon to plan the safest route to the tumour and 
intra-operatively to maximise safe resection. Conventional imaging post contrast T1 
weighted images with thin slice protocols are generally acquired for image guidance 
software registration and the increased spatial resolution of such sequences compared 
to the usual diagnostic scans has been highlighted in the discussion of detection. 
Diffusion imaging allows images of white matter tracts and their relationship to 
tumour to be delineated. DTI acquisitions, in addition to generating quantitative 
parameters, can permit tractography by estimating the directionality of fibre tracts, 
permitting the tracking of fibre bundles in 3D space. The methodology for this post 
processing varies and a number of non-proprietary software solutions in addition to 
those supplied by manufacturers are available. Further refinements to the 
methodology, including use of higher order algorithms to resolve ambiguous 
directionality on voxels may further increase reliability (Farquharson et al., 2013). 
Functional MR detects changes in blood oxygen level or BOLD signal in 
metabolically more active areas during application of a stimulus or performance of a 
task. This is particularly useful to localise language areas or motor cortex. Few series 
have examined the role of fMRI in metastases resections alone, but in those that 
have, significant benefits in terms of motor recovery, preservation and therefore 
quality of life have been demonstrated (Walter et al., 2011). Modern software can 
integrate functional and tractography sequences into a single merged dataset for use 
in theatre. Whilst there are limitations on the accuracy of image guidance systems, 
ranging from the fidelity of the preoperative MRI scan to the type of image 
registration algorithms applied (Widmann et al., 2012) and the problems of brain 
shift (Kuhnt et al., 2012) where the pre-registered navigation is rendered inaccurate 
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once CSF is released, there are nonetheless improved outcomes reported for surgical 
series looking exclusively at metastases (Tan and Black, 2007, Paek et al., 2005).  
 
Figure 1.6: A patient known to have breast cancer with a manually dexterous job presented 
with intermittent left hand and arm weakness and was found (A) to have a solitary ring 
enhancing lesion in the premotor area on T1W MRI with gadolinium. (B) Functional MRI 
performing a hand tapping and gripping task determined the location of hand function and 
this was used as the “seed” region of interest on a DTI scan to produce a representation of 
the motor tracts. (C) These were used to generate a 3D object and fused with an anatomical 
planning scan (1 mm slices) using commercially available software (StealthViz™ with 
StealthDTI™ by Medtronic, running on an S7 workstation) to produce images that were used 
intraoperatively for image guided resection, avoiding the tracts (shown in red, with tumour 
rendered in green). 
 
1.5.2.4 Predicting the primary cancer 
In cases of multiple metastasis or solitary lesions with no known primary, MRI may 
give useful diagnostic clues as to the original tumour. Some primaries may have 
particular signal characteristics even on conventional MR. For example melanoma 
metastases may show high signal on non-enhanced T1 sequences due to the effect of 
melanin and mucinous metastases may show low T2 signal compared with the 
expected hyper-intensity on this sequence. The metabolic profile has been 
investigated for metastases of differing primary tumours as well as the surrounding 
brain, with no abnormal spectra reported outside of the lesion itself. Metabolic 
features on MRS have shown limited value in predicting primary type. However, 
raised mobile lipid content has been proposed as a weak sign of a colonic origin 
metastasis (Chernov et al., 2006). Others have tried to use the diffusion 
characteristics of particular metastases to distinguish the primary and, whilst it has 
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been shown that ADC values are higher in well differentiated adenocarcinoma 
metastases than poorly differentiated types, this may simply reflect cellularity and 
could not predict the primary, only suggest a narrower differential (Hayashida et al., 
2006). Likewise in a series with a variety of primary cancers including lung and 
breast, restricted diffusion could not be correlated with any primary nor could ADC 
predict primary pathology (Duygulu et al., 2010).  Spectroscopy was combined with 
perfusion MR to show that differences in choline-creatine ratios between metastases 
of lung and breast cancer correlated with differences in relative cerebral blood 
volume, but tissue was not available for comparison to look for a unifying 
pathological basis (Huang et al., 2010).  
Summary: MRS may be used to distinguish primary tumour origin. However, more 
than one advanced MR metric may need to be combined in order to robustly generate 
models that differentiate the primary lesion and, though these studies would likely be 
retrospective, ideally some image guided correlation of regions of interest on the 
advanced MR with the final tissue samples is needed, as has been performed for 
glioma (Price and Gillard, 2011). 
 
1.5.2.5 Monitoring response to treatment  
Beyond diagnosis, MRI may be used to monitor response to treatment as part of 
clinical and radiological follow up. This may be immediate, as in post-operative MRI 
to determine if there has been a complete resection, or delayed, i.e. has the metastasis 
responded to chemo- or radio-therapy.  In general, conventional sequences are 
utilized, but one area of particular clinical interest in following cases up is ongoing or 
increasing enhancement following stereotactic radiosurgery to a metastasis and 
whether this represents radio-necrosis or recurrence (Kang et al., 2009). Standard 
patterns of changes in brain metastases are seen on conventional MRI with peri-
lesional oedema, central hypo-intensity on T2 weighted imaging at 2-6 months 
followed by blurring of the enhancement margin, reduction in enhancing volume 
over time and formation of a glial scar (Peterson et al., 1999, Lunsford et al., 1998, 
Friedman et al., 2001). Although attempts have been made to build discriminatory 
measures from conventional MRI (Dequesada et al., 2008) performance has proven 
disappointing (Stockham et al., 2012).  Blood flow would be expected to differ 
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significantly between areas of necrosis and recurrence. MR perfusion has shown 
higher rCBV in recurrent metastases after radiosurgery compared to areas of 
radionecrosis and reduction in CBF over time for treated lesions (Hoefnagels et al., 
2009, Barajas et al., 2009). Furthermore, the first reading of CBF following treatment 
was highly predictive of the final response, even though pre-operative readings could 
not predict this. Diffusion imaging may reflect cellularity and ADC readings from 
metastases treated with radiosurgery, taken immediately post treatment may be 
tracked to determine if the lesion is responding to therapy, manifest as increasing 
ADC, as compared to a recurring or necrotic lesion where the changes in ADC differ. 
The initial ADC value may also predict final response to the treatment (Goldman et 
al., 2006). In conjunction with perfusion MRI, this suggests the novel application of 
advanced MR readings, not just as diagnostic tools but as predictors of future 
treatment response or biological markers. 
Figure 1.7: 
Monitoring of 
treatment 
response after 
stereotactic 
radiosurgery. 
A patient with 
known 
metastatic 
melanoma 
underwent 
treatment to a 
left frontal 
lesion (A) and 
at 3 months 
(B) the 
characteristic changes of a blurred margin and necrosis followed by formation of a glial scar 
at 6 months (C) are seen. However in a similar appearing patient (D) with a right parietal 
lesion from metastatic renal cell carcinoma, the lesion shows more florid changes at 3 
months (E) with increased contrast enhancement at the margins and the possibility of 
progression, as opposed to radionecrosis is raised. Multi-modal techniques described in the 
text may show promise in deciding how to proceed at this stage. The patient was well and on 
monoclonal antibody chemotherapy, with observation the lesion eventually regressed at 6 
months (F) and is currently stable. 
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1.5.2.6 Predicting survival 
As described in many studies here, various metrics or measurements may be taken 
from the different advanced MR images described using the device workstation or 
non-proprietary software. A biological marker or “biomarker” is strictly any such 
reading which is used for diagnostic or prognostic purposes. Even conventional MR 
may provide such markers, and it has been shown that for solitary metastases in one 
series, the degree of oedema on the preoperative T2 weighted scan was related to the 
degree of angiogenesis, brain invasiveness and overall survival with reduced oedema 
surprisingly being a worse prognostic factor (Spanberger et al., 2013b). The role of 
ADC and CBF in predicting response of metastases to SRS has been discussed in the 
preceding section. Berghoff and colleagues took readings from preoperative DWI in 
single metastases which were subsequently resected. They found a reduced overall 
survival, irrespective of adjuvant treatments and denser reticulin (stromal) matrix in 
patients with low tumoural ADC compared to the group mean (Berghoff et al., 
2013c). These measures could potentially be incorporated into the prognostic models 
mentioned such as the recursive partitioning score (RPA) or graded prognosis 
assessment (GPA) score; widely validated predictors of survival in brain metastases 
patients which combine clinical information such as age, status of the primary cancer 
and extracranial disease amongst others (Sperduto et al., 2008, Gaspar et al., 1997). 
Further standardisation of the post processing and measurement workflow is needed, 
however, before MRI metrics could be confidently used in clinical practice. 
 
1.5.2.7 Future directions 
As cancer diagnostics and therapeutics become increasingly related, three areas of 
emerging MR technology with practical applications to brain metastases stand out. 
Integration of cancer staging via PET-MR offers one potential means of 
incorporating further functional data in real time without losing all the knowledge 
already acquired about the behaviour and characteristics of metastases on MRI 
(Torigian et al., 2013). Novel contrast agents, including those that can identify 
molecular targets, are in development in animals and an agent based on iron oxide 
particles which bind to a vascular cell adhesion molecule common to human 
metastases has been used to visualise micro-metastases at MRI, suggesting the 
R ZAKARIA - PHD THESIS: LOCAL INVASION IN CEREBRAL METASTASES                              -16-    
possibility of diagnosing and possibly treating brain metastases long before they 
were previously even detected (Serres et al., 2012). Finally the application of MR as 
an intraoperative tool for guiding minimally invasive therapies such as laser 
coagulation or high intensity focused ultrasound is no longer conceptual, with several 
small series of treated tumours including metastases being reported (Jethwa et al., 
2012, Ram et al., 2006). MR technology will continue to enhance diagnosis but is 
now being used to predict prognosis and being incorporated into the treatment of 
metastases too (Monteith et al., 2013). 
 
1.5.3 Histopathology  
 
Due to increasing concern regarding the adverse effects of radiotherapy treatment, 
more tailored chemotherapy regimens and the presence of common mimics such as 
lymphoma and glioma, imaging diagnosis alone for brain metastases is essentially 
insufficient, even with a persuasive clinical picture. In such situations tissue may be 
obtained by resection (if indicated clinically – see Section 1.6.1) or biopsy and 
analysed by a specialist neuropathologist for macroscopic features and microscopic 
morphology. This is supported by IHC, including, but not limited to, cytokeratins 
(CK7 for lung, breast origin versus CK20 for colorectal, pancreatic, urothelial), EMA 
(carcinoma), S-100 (melanoma, glioma), TTF-1 (small cell and lung 
adenocarcinoma) and Ki67 (marker of proliferation)(Pekmezci and Perry, 2013). 
Ancillary tests such as HER2 status for breast cancers or EGFR receptor status for 
lung adenocarcinomas may be added as required and primary tissue from any 
previously operated cancer is reviewed. 
 
1.6 Treatment 
 
Treatment of patients with brain metastases is not directed at curing the disease, but 
rather extending survival with as high a quality as possible. Patients may present late 
in the course of their systemic disease and be appropriate for palliation only, but for 
those patients with a good level of function (generally taken to mean they can care 
for themselves), brain metastases are treated by a combination of surgery, 
radiotherapy – either focal or to the whole brain – and chemotherapy. Management is 
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collaborative through a multidisciplinary team (MDT) of the relevant specialities 
including neurosurgery, oncology, radiology, pathology, nurses and therapists. There 
are a number of randomised controlled trials comparing these different treatments 
and their combinations, but guidelines in the United Kingdom, North America and 
Europe reflect deep uncertainty about which therapies to use and in which patients.  
 
 
1.6.1 Surgery  
 
Neurosurgical resection of brain metastases, usually performed for solitary tumours, 
provides tissue for diagnosis (see Section 1.5.3) and relieves mass effect. 
Neurosurgery followed by whole brain radiotherapy (WBRT) prolonged functional 
independence, local control and overall survival compared to biopsy and WBRT in a 
randomised controlled trial (Patchell et al., 1990) and compared to WBRT alone in a 
meta-analyses of randomised controlled trials (Hart et al., 2005).  Local recurrence 
rates for solitary metastases after neurosurgery are approximately 15-20% across a 
variety of settings (Patel et al., 2010, Jenkinson et al., 2011) although more 
aggressive surgical resection of the metastasis margins in non-eloquent areas may 
reduce this (Yoo et al., 2009). Risks of neurosurgery include a general anaesthetic, 
risk to life, bleeding, infection and neurological impairment. The latter is reduced by 
the use of modern image guidance techniques (Tan and Black, 2007), as described in 
Section 1.5.2. Nonetheless, hemiparesis may occur more often than expected, even 
with intraoperative monitoring of motor cortical tract function, in keeping with these 
tumours being more locally invasive, or more gliomatous, than previously thought 
(Obermueller et al., 2015).  
 
1.6.2 Radiotherapy 
 
1.6.2.1 Stereotactic radiosurgery  
Stereotactic radiosurgery (SRS) is the administration of high doses of radiation to a 
focal target sparing as much of the surrounding tissue as possible. This is delivered in 
a single dose (strictly this is the true definition of SRS) or in fewer than five doses 
for larger tumours (this is hypo-fractionated or stereotactic radiotherapy (SRT), but 
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often referred to as SRS and grouped under SRS in the medical literature). A variety 
of technologies or platforms are used to deliver SRS including Gamma Knife ®, 
Cyberknife ® and linear accelerators (LINAC).  
 
SRS is therefore a focal treatment for brain metastases and can be performed in the 
outpatient setting or as a day case, without fixation on some devices and without 
anaesthesia, if tolerated. Although never compared directly to surgical resection in a 
trial setting, case series suggest SRS is non-inferior to surgery when both are 
combined with WBRT (Schöggl et al., 2000) and is certainly more cost effective 
(Mehta et al., 1997). In UK clinical practice, SRS is reserved for treating 1-3 smaller 
tumours (risk of radionecrosis increases with increasing size, so an upper limit of 
20cc is used), where there is little oedema or mass effect, and the patient is expected 
to survive 6 months (NICE – reference NHSCB/ D05/P/d). 
 
Neurosurgery SRS 
Significant mass effect No midline shift or CSF pathway obstruction 
Superficial or non-eloquent location Deep seated or difficult to access  
Large, solitary lesion 
Tissue needed for diagnosis, e.g. 
cancer of unknown origin or no primary 
found after staging studies  
Radio-resistant histology, if known 
 
Radiosensitive histology if already known 
Small volume of tumour overall (e.g. under 
30mm diameter) or small number of tumours in 
older schemes (e.g. ≤ 3) 
Medically unfit or high risk for anaesthesia e.g. 
warfarin for metallic heart valve, restrictive lung 
disease 
 
Table 1.1: Factors favouring neurosurgery or stereotactic radiosurgery (SRS) as the 
treatment of choice for brain metastases. CSF = cerebrospinal fluid, mm = millimetres. 
 
 
Elsewhere, SRS is being increasingly used, both as an alternative to WBRT in 
patients with multiple metastases (Yamamoto et al., 2014), and in addition to 
neurosurgery as a “boost” (Ojerholm et al., 2014). Indeed a randomised trial of SRS 
to the cavity after neurosurgery is underway in North America (ClinicalTrials.gov 
Identifier: NCT01372774) and markers of local invasion and radiosensitivity will 
thus be urgently required to stratify patients for such treatments in the future. 
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1.6.2.2 Whole brain radiotherapy  
 
Whole brain radiotherapy (WBRT) is usually delivered as 30Gy in 10 fractions as an 
adjunct to a local therapy or as a palliative measure on its own for those unsuitable 
for more aggressive treatments. Support for the former is well established with 
randomised trials showing reduced intracranial progression and fewer salvage 
therapies needed in those irradiated compared to those simply observed after either 
SRS (Kocher et al., 2011) or neurosurgery (Patchell et al., 1998). An improvement in 
overall survival was never proven and with recent evidence suggesting patients may 
get deleterious cognitive effects within months of WBRT (Chang et al., 2009), this 
result has been used to justify omitting WBRT after local treatments (Tsao et al., 
2012). Even for those not receiving any active local therapy, a large study has 
suggested WBRT may be worse in terms of quality of survival than optimal 
palliative care (Langley et al., 2013). Despite these studies, WBRT remains easy to 
access and administer in most healthcare systems, whilst progressive disease - even if 
it does not affect survival - may cause just as many harmful cognitive effects as 
radiation; thus the balance of where this risk lies is not yet defined (Kondziolka et al., 
2014). What will be needed are markers of local invasion, radiation response and 
intracranial progression to allow optimisation of therapy (i.e. the correct balance of 
risks and benefits) for individual patients.  
 
 
1.6.3 Chemotherapy  
 
All patients are routinely managed with dexamethasone or oral steroid equivalent at 
high dose, typically 8-16 mg in divided doses tapered off as quickly as tolerated over 
the course of treatment (Soffietti et al., 2006). Systemic chemotherapy for the 
primary cancer is generally continued during surgery or radiation therapy - if already 
instated - or administered once these treatments have finished if not, although from 
an oncological point of view, the central nervous system has been regarded as a 
sanctuary site with limited effectiveness of systemic chemotherapy.  
Strategies (Puhalla et al., 2015) therefore include: 
 
R ZAKARIA - PHD THESIS: LOCAL INVASION IN CEREBRAL METASTASES                              -20-    
 facilitating passage of known systemic chemotherapy agents across the 
blood-brain or rather blood-tumour barrier (Connell et al., 2013) 
 identifying anti-metastatic effects amongst agents already known to function 
in the brain (Abel et al., 2013) 
 developing agents that may act systemically to prevent spread of metastatic 
cells in the systemic circulation into brain, for example by reducing 
circulating tumour cell load (Pierga et al., 2013) 
 administering chemotherapy before surgery to alter the immune response or 
behaviour of the operated tumour (Jones et al., 2015) 
 
 
1.6.4 Summary of treatment options 
 
The evidence and treatment options are highly varied. Trials include patients with 
metastases from different primary cancers, hence there are a wide range of outcomes 
seen and it is difficult for clinicians to generalise even the more robust results to the 
individual patient with a particular primary tumour. In general, comparing WBRT 
alone to local therapies with WBRT, combined treatment seems to improve overall 
survival and control of brain disease. When considering whether to add WBRT or 
not after a local treatment, the addition of WBRT may result in improved control of 
brain disease and hence reduced death from neurological causes, but it does not 
necessarily improve the overall survival. This is especially true for oligometastatic 
disease compared to solitary metastases. There is conflicting data about the cognitive 
and quality of life effects of WBRT and any strategy which omits this treatment must 
show active monitoring for progression, which may itself cause these effects. In 
terms of local therapies, surgery is still the standard of care for large, solitary, 
accessible lesions with significant mass effect or oedema and adjuncts, such as 
image-guidance and extensive resection, may improve local control further. Detailed 
treatment information must therefore be taken into account and clear outcome 
measures used when studying patients with cerebral metastases. 
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1.7 Outcomes and their estimation 
 
The wide variation in prognosis from brain metastases has led to a number of scoring 
systems which have been adopted into clinical practice in order to guide decision 
making and, in particular, select patients for aggressive treatment. All of these 
incorporate an assessment of functional impairment, scored using a set scale by a 
treating healthcare professional and encompassing the patient’s ability to care for 
themselves (Schag et al., 1984, Karnofsky DA, 1949).  
 
Able to carry on normal activity and to work; 
no special care needed. 
100 
Normal, no complaints; no evidence 
of disease. 
90 
Able to carry on normal activity; minor 
signs or symptoms of disease. 
80 
Normal activity with effort; some signs 
or symptoms of disease. 
Unable to work; able to live at home and care 
for most personal needs; varying amount of 
assistance needed. 
70 
Cares for self; unable to carry on 
normal activity or to do active work. 
60 
Requires occasional assistance, but is 
able to care for most of his personal 
needs. 
50 
Requires considerable assistance and 
frequent medical care. 
Unable to care for self; requires equivalent of 
institutional or hospital care; disease may be 
progressing rapidly. 
40 
Disabled; requires special care and 
assistance. 
30 
Severely disabled; hospital admission 
is indicated although death not 
imminent. 
20 
Very sick; hospital admission 
necessary; active supportive treatment 
necessary. 
10 
Moribund; fatal processes progressing 
rapidly. 
0 Dead 
 
Table 1.2: The Karnofsky performance scale (KPS) which is used to classify functional 
impairment in patients with cerebral metastases. 
 
In the early Recursive Partitioning Analysis (RPA) score (Gaspar et al., 1997), data 
was pooled from approximately 1200 patients and they were assigned to one of three 
categories based on the Karnofsky performance scale (KPS), their age and the status 
of their primary cancer (whether it is controlled and without other metastases). This 
score was used to predict the overall survival time and has been widely validated in 
clinical practice, but criticised for not taking into account the number of cerebral 
metastases. Hence the Graded Prognostic Assessment (GPA) score which was based 
on an expanded database from the RTOG (Sperduto et al., 2008) and assesses age in 
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more categories and includes number of lesions. Most recently the idea that “all 
cerebral metastases are created equal” gave way to the disease specific GPA score 
(Sperduto et al., 2010), with different factors seen as being important for different 
types of tumour histology (reproduced in Table 1.3). 
 
 
Table 1.3: Scoring system to predict the overall survival of patients with cerebral metastases 
based on clinical and pathological features from (Sperduto et al., 2012).  
 
These scores, though useful in trials and widely used by some oncologists, are still 
felt to be unsatisfactory in clinical practice. Clinicians are poor at estimating 
prognosis (Jakola et al., 2012, Zakaria and Jenkinson, 2015), there is too wide a 
variation within categories (Grossman and Ram, 2014) and scoring systems are 
based on cohorts treated with surgery, radiation and chemotherapy. Furthermore, 
there is no incorporation radiological data and little use of biological data in these 
scores and no systems for estimating time to intracranial progression nor radiation 
sensitivity, despite the importance of these features for patients and healthcare 
professionals. 
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1.8 Statement of the problem and outline of the thesis hypotheses 
 
Cerebral metastases are increasingly common and cause significant morbidity, 
threatening to limit the gains made in treating common solid organ cancers. Despite 
this, there is a lack of consensus surrounding the best treatment strategies and, in 
particular, how to combine local treatments (surgery, SRS) with WBRT. Better 
understanding of the biological mechanisms of local brain invasion by these tumours 
is urgently needed, not only to inform these strategies but also to enable improved 
prediction of clinical outcomes such as intracranial progression.  
 
The aim of this thesis is to derive biological and radiological markers of local brain 
metastasis invasion, intracranial progression and survival which may be used in 
clinical practice, whilst deepening scientific understanding of the brain-brain 
metastasis interface.  
 
Chapter 2 describes the investigation of metastasis-inducing protein expression in a 
series of brain metastases and their clinical importance as possible biological markers 
of survival, recurrence and radiation sensitivity.  
Hypotheses: Proteins which induce a metastatic phenotype in solid organ cancers are 
also involved in local invasion in brain metastases. Levels of expression of such 
proteins may be associated with clinical outcomes such as survival and progression 
for patients with brain metastases. 
 
Chapter 3 describes the MRI analysis of the brain-brain metastasis interface. This is 
presented in the form of two published papers, one determining the methodology and 
the other the analysis itself.  
Hypotheses: Measurements may be taken from diffusion weighted MRI brain scans 
of patients with brain metastases with high reliability on clinical grade hardware and 
software. These MRI measures may be associated with clinical outcomes such as 
survival and progression in patients with brain metastases. Specifically, the change in 
apparent diffusion coefficient at the brain-brain metastasis interface may be 
predictive of survival after resection of that brain metastasis.  
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Chapter 4 describes a prospective study in which the brain-brain metastases interface 
was examined using image-guided neurosurgical sampling alongside MRI analysis of 
the co-localised regions of interest to bring together the previous work in an 
integrated analysis of the tumour leading edge and peritumoural region.  
Hypotheses: Differences between tumours in diffusion weighted MRI characteristics 
at the brain-brain metastasis interface reflect underlying differences in invasive 
growth pattern, metastasis inducing protein expression and markers of aggressive 
behaviour such as vascularity, cellularity and proliferation. This relation explains 
why the MRI measures are predictive of clinical outcomes. 
 
Chapter 5 discusses the implications of the thesis findings, whether the hypotheses 
were proven and the future directions for study. 
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Chapter 2: Biological markers of local invasion 
2.1 Abstract  
Background: Understanding the factors that drive recurrence and radiosensitivity in 
brain metastases would improve prediction of outcomes, treatment planning and 
development of therapeutics. We investigated the expression of known Metastasis-
Inducing Proteins in human brain metastases. 
Methods: Immunohistochemistry on metastases removed at neurosurgery from 138 
patients to determine the degree and pattern of expression of the proteins S100A4, 
S100P, AGR2, osteopontin (OPN) and the DNA repair marker FANCD2. Validation 
of significant findings in a separate prospective series with investigation of intra-
tumoural heterogeneity using image-guided sampling. Assessment of S100A4 
expression in brain metastatic and non-metastatic primary breast carcinomas.  
Results: There was widespread staining for OPN, S100A4, S100P and AGR2 in 
human brain metastases. Positive staining for S100A4 was independently associated 
with a shorter time to intracranial progression after resection in multivariate analysis 
(hazard ratio for negative over positive staining = 0.17, 95% CI: 0.04 – 0.74, 
p=0.018). S100A4 was expressed at the leading edge of brain metastases in image 
guided sampling and overexpressed in brain-metastatic versus non-brain metastatic 
primary breast carcinomas. Staining for OPN was associated with a significant 
increase in survival time after postoperative whole brain radiotherapy in 
retrospective (OPN negative 3.43 months, 95% CI: 1.36 – 5.51 vs. OPN positive, 
11.20 months 95% CI: 7.68 – 14.72, Log Rank test, p<0.001) and validation 
populations. 
Conclusions: Proteins known to be involved in cellular adhesion and migration in 
vitro and metastasis in vivo are significantly expressed in human brain metastases 
and may be useful biomarkers of intracranial progression and radiosensitivity.  
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2.2 Introduction 
Brain metastases (BMs) are common brain tumors in adults with a steeply rising 
incidence due to the increased use of brain imaging in asymptomatic patients and 
prolonged survival from solid organ cancers (Owonikoko et al., 2014). There are no 
known biological markers that are routinely used to predict patient outcomes in BMs. 
Clinical factors are combined to generate predictions of overall survival, but cannot 
predict intracranial progression and the various models are not individualised to each 
patient, even if different primary cancer types are assessed separately (Sperduto et 
al., 2010).  
We have previously identified two groups of proteins in the rat mammary model 
system that can induce metastasis and are associated with clinical outcomes in 
patients with breast (de Silva Rudland et al., 2011) and other solid organ cancers. 
S100A4 and S100P are small calcium-dependent regulatory molecules that probably 
work by inducing cellular migration and invasion directly (Gross et al., 2014).  
S100A4 is active in the brain microenvironment (Dmytriyeva et al., 2012), elevated 
levels are associated with a metastatic phenotype, it cooperates with growth-inducing 
activated oncogenes to yield growing metastases and carcinomas in S100A4 
knockout mice do not metastasise to brain.(Bresnick et al., 2015) The second group – 
osteopontin (OPN) and anterior gradient 2 (AGR2) - work primarily by inducing 
cellular adhesion to the ECM that then allows migration to take place (Moye et al., 
2004, Liu et al., 2005). OPN binds the cell surface integrins αVβ3 / αVβ5 with the 
latter widely expressed in human BMs and their microenvironment (Schittenhelm et 
al., 2013, Berghoff et al., 2014). The integrin αVβ3 / αVβ5 inhibitor cilengitide induces 
cellular detachment and apoptosis, and reduces proliferation in a panel of brain 
metastatic breast cancer cell lines (Lautenschlaeger et al., 2013). AGR2 has been 
shown to be necessary and sufficient for migration in vitro in a glioblastoma cell line 
(Hong et al., 2013). Finally, the underlying change that is believed to result in 
selection for overexpression of these Metastasis-Inducing Proteins (MIPs) is a failure 
of ds DNA repair  in a progenitor cell and in the breast this process is identified by 
immunohistochemical loss of FANCD2 (Rudland et al., 2010); the related proteins 
FANCA and FANCG have recently been shown to be overexpressed in BMs 
compared to the primary breast carcinoma in paired human samples (Woditschka et 
al., 2014).  
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2.3 Materials and methods 
2.3.1 Patients and specimens 
Patients with a diagnosis of brain metastasis were identified from histopathology 
records between 2005 and 2012 at a single institution and formalin-fixed, paraffin-
embedded specimens were obtained in 138 cases. Full clinical information was 
gathered and is summarised in Table 2.1. 
 
Table 2.1: Summary of clinical and radiological characteristics of 138 patients with operated 
brain metastases and their treatment following neurosurgery. 
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For validation and investigation of intratumoral heterogeneity, 24 consecutive 
patients were included who underwent neurosurgical resection of a solitary 
supratentorial metastasis in non-eloquent brain by image-guided craniotomy as part 
of their standard care from 2014 - 2015. Clinical details are listed in Table 2.2 and 
surgical, MRI techniques have been described previously (Zakaria and Jenkinson, 
2014). Primary breast carcinoma specimens were obtained from partner tissue banks 
locally and ethical approval was granted within the Walton Research Tissue Bank 
(NRES 11/WNo03/2) and by the UK Health Research Authority (NRES 
12/NW/0778).  
Table 2.2: Clinical data for prospective series of 24 patients with resected supratentorial 
metastases. 
Age at surgery   (median, range) 59.3 years (23.9 – 76.0) 
Gender Female 13 54% 
Male 11 46% 
Primary carcinoma Non-small cell lung  12 50% 
Melanoma 4 17% 
Breast 3 13% 
Colorectal 2 8% 
Endometrial 1 4% 
Renal 1 4% 
Sarcoma 1 4% 
Extracranial disease? Absent 17 71% 
Present 7 29% 
Controlled primary? Synchronous presentation 8 33% 
Yes 16 67% 
Adjuvant whole brain 
radiotherapy? 
No 5 21% 
Yes, 30 Gray in 10# 19 79% 
Adjuvant chemotherapy? No 13 54% 
Yes 11 46% 
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2.3.2 Immunohistochemistry  
Acknowledgement: This section was largely written by Mrs Angela Platt-Higgins 
BSc, scientist at the Institute of Integrative Biology. 
Histological sections were cut at 4 µm on APES coated slides, dewaxed in xylene 
and rehydrated through graded ethanol to water. Firstly, endogenous peroxidase 
activity in the tissue sections was blocked by immersing the slides in 100% methanol 
containing 0.05% (v/v) H202 for 20 min at room temperature. Sections were then 
incubated in a moisture chamber with antibodies diluted in phosphate-buffered saline 
(PBS) containing 1% (w/v) bovine serum albumen (BSA), pH 7.4. 
Polyclonal affinity-purified anti-AGR2 (13) (#ARP42290, Aviva Systems Biology, 
San Diego, CA) was used at a dilution of 1:750 in phosphate-buffered saline (PBS) 
containing 2% (w/v) bovine serum albumen (BSA) pH7.4 and monoclonal anti-
osteopontin (#MP111B10, Developmental Studies Hybridoma Bank, Iowa City, IA, 
USA) was used at 1:300 in 0.5% (w/v) BSA. Both were incubated on the sections 
overnight at 4
o
C. Polyclonal anti-S100A4 (#A5114, Dako UK Ltd, Ely, 
Cambridgeshire) and monoclonal anti-S100P (#610307, BD Biosciences, Oxford 
Science Park, Oxford) were used at a dilution of 1:400 and 1:75 respectively and 
were incubated for 2hr at room temperature, following an initial pre-incubation with 
2% (w/v) BSA in PBS for 30 min at room temperature on the sections. Polyclonal 
anti-FANCD2 (#H300; sc28194, Santa Cruz Biotechnology Inc., Dallas, Texas, 
USA) was used at a dilution of 1:300 and was incubated for 3hr at room temperature, 
again following a 30 minute pre-incubation with 2% (w/v) BSA on the sections.  
FANCD2 antibodies recognize both the non-monoubiquitylated and 
monoubiquitylated isoforms of FANCD2 (Wilson et al., 2008). Polyclonal anti-
GFAP (#Z0334, Dako) and monoclonal anti-CD34 (#M7165, Dako) were used at a 
dilution of 1:2000 and 1:25 respectively and incubated on the sections for 1hr at 
room temperature.  Prior to incubation, a 5 minute Proteinase K (Dako) digestion 
step was carried out by following the manufacturer’s instructions.  After all the 
above antibody incubations, sections were thoroughly washed in three changes of 
PBS.  
Indirect immunohistochemical staining was carried out using an enhanced 
horseradish peroxidase (HRP) labelled polymer system, the DAKO 
R ZAKARIA - PHD THESIS: LOCAL INVASION IN CEREBRAL METASTASES                              -30-    
EnVision+System, peroxidase(DAB) (Heras A, 1995) with reagents prepared 
according to the manufacturer’s instructions.   After a final wash in running tap 
water, all sections were counterstained in Mayers' haemalum before being 
dehydrated through graded ethanol and xylene and mounted using DPX mountant 
(VWR, Lutterworth, Leicestershire).  
 
For melanoma metastases a red coloured chromogen (AEC)(Dako) was used to avoid 
confusion with pigmented, brown/black melanin-containing cells.  This is illustrated 
in Figure 2.1. In this case, the sections were mounted, without dehydration, using a 
water soluble mountant (Glycergel, Dako).   
 
Figure 2.1: Immunohistochemical staining for the protein osteopontin in a 52 year old patient 
with metastatic melanoma who underwent craniotomy and resection. The H&E stained 
section (A) shows tumour cells with irregular, enlarged nuclei. Using standard antibody 
detection kits there seems to be evidence of protein expression in the cytoplasm 
predominantly (B), but the presence of brown and black melanocytes (C) makes it difficult to 
judge. Use of an alternative antibody detection kit with a red chromogen allows confirmation 
of staining (D) in tumour cells. Original magnification X 200. Bars= 100 µm. 
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Non immune sera consisting of mouse IgG (Abcam) for mouse monoclonal 
antibodies (OPN and S100P) and rabbit IgG (Abcam) for rabbit polyclonal 
antibodies (S100A4 & AGR2) were substituted for primary antibodies and were 
included in each staining run.  Breast carcinoma sections that were known to express 
all the proteins were used as external positive controls. Antigen-blocked immune 
serum was prepared by prior incubation with the appropriate recombinant protein as 
in previous studies on S100A4 (de Silva Rudland et al., 2006), S100P (Wang et al., 
2006) and FANCD2 (Rudland et al., 2010). Additionally AGR2 and OPN antibodies 
were blocked by pre-incubating it with the appropriate blocking peptides (# 
AAP42290 for AGR2and #AAP36677 for OPN, Aviva) in the ratio 100:1, Ag:Ab, 
with final antibody concentrations of 1:750 and 1:300 respectively.  Blocking peptide 
pre-incubations were performed over 72hrs at 4°C. The control sera were then used 
in the immunohistochemical procedure as described above. 
 
 
2.3.3 Assessment of staining 
Slides were analysed independently by two observers using light microscopy and 
corroborated by a senior neuropathologist. The percentage of nuclear and/or 
cytoplasm stained tumor cells was recorded from well-separated sections of each 
specimen, 10 fields per section at ×200 magnification, at a minimum of 200 cells per 
field in a rigorous fashion as described previously (Wang et al., 2006). There was 
agreement on positive staining (1% or above of cells positively stained to any degree 
(de Silva Rudland et al., 2011)) in 94% of slides scored, with a kappa statistic of 
0.884. Slides were photographed using a Leica DFC310FX camera attached to a 
DM2000 microscope with the LAS V3 software suite (Leica microsystems, 2014) 
with no additional filtering or post processing of images.  
 
2.3.4 Statistical methods 
Time from surgery to death was recorded as overall survival (OS) and non-cancer 
deaths or those lost to follow up censored at last recorded follow up. Progression free 
survival (PFS) was recorded as time from surgery to documented intracranial 
progression as assessed by neuroradiologists using standard (RANO) criteria(Quant 
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and Wen, 2011). Patients who died before this point were censored at the last date of 
follow up where there was no evidence of progression. Proportions were assessed 
using Fisher’s two-sided exact test. Time to event comparisons were made using 
Kaplan-Meier survival analysis with Log Rank tests and multivariate analyses 
conducted using Cox’s method. Data processing was performed using SPSS version 
22.0 (IBM, Chicago, IL) and R version 3.10 (R Core (Team, 2013)). 
 
2.4 Results 
2.4.1 Exploratory immunohistochemical staining  
Of 138 BMs assessed retrospectively, sixteen were negatively stained for OPN 
(11.6%) and 122 (88.4%) were positively stained in varying proportions and 
intensities. This staining was mainly cytoplasmic with a stippled pattern, although 
some nuclear staining was also noted (Figure 2.2A). For AGR2 38 (27.5%) BMs 
were negatively stained, whilst 100 (72.5%) showed cytoplasmic staining. BMs from 
the posterior fossa that included cerebellar cortex showed incidental positive staining 
of what appeared to be the granule cells, but this did not affect the tumour staining 
analysis (Figure 2.2B).  Assessment for S100P staining was positive (nuclear and 
cytoplasmic) in 102 BM (73.9%) cases, negative in 36 (26.1%). In areas of white 
matter adjacent to tumour, occasional astrocytes were seen to stain with anti-S100P 
antibody (Figure 2.2C), however, morphology and staining of serial sections with 
GFAP clarified that these were not tumour cells, thus avoiding any false positives. 
Glial staining for the purposes of this study was not considered further. For S100A4, 
32 BMs (23.2%) were negative and 106 (76.8%) stained to some degree (Figure 
2.2D). Staining was both nuclear and cytoplasmic, however smooth muscle and 
endothelium were also seen to stain avidly with this antibody as noted previously. 
There was no staining of astrocytes nor peritumoural staining for S100A4 or OPN 
(Figure 2.2 A,D).  The heterogeneity of tissue staining was better appreciated in 
lower power micrographs (Figure 2.3). There was no staining with antigen-blocked 
immune serum (Figure 2.2) or with non-immune serum (Figure 2.4) as negative 
controls. The majority of BMs (113 or 81.9%) showed no immunoreactivity for 
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FANCD2: only 25 (18.1%) showed weak cytoplasmic staining and there was no 
nuclear staining in any cases.  
 
Figure 2.2: Staining for the Metastasis-Inducing Proteins in human brain metastases. A. 
Osteopontin in the tumour cytoplasm of a lung adenocarcinoma metastasis with some 
staining of the neuropial material in adjacent white matter. White matter and microglia, 
astrocytes were easily distinguished morphologically from tumour cells and their staining was 
not counted when scoring slides. B. AGR2 staining was seen mainly in the cytoplasm with no 
uptake in surrounding white matter as shown in this lung adenocarcinoma metastasis. C. 
S100P staining in a lung adenocarcinoma with adjacent white matter shown – this protein, as 
in previous studies, was overexpressed in connective tissue and smooth muscle. D. Nuclear 
and cytoplasmic staining for the protein S100A4 is shown in a brain metastasis from a breast 
carcinoma with avid staining of the endothelium also demonstrated.  Taken at x100 and x400 
magnification with scale bars shown (=100µm) and antigen-blocked immune serum controls 
given alongside. 
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Figure 2.3: Photomicrographs at lower magnifications to demonstrate intratumoral 
heterogeneity of staining.  
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Figure 2.4: Negative controls: Non immune sera consisting of mouse IgG (Abcam) for mouse 
monoclonal antibodies (OPN & S100P) and rabbit IgG (Abcam) for rabbit polyclonal 
antibodies (S100A4 & AGR2) were substituted for primary antibodies and were included in 
each staining run. 
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2.4.2 Association between MIPs and primary cancer type, clinical features 
Figure 2.5 and Table 2.3 show positive BM staining for each MIP by primary cancer type. 
There was no significant variation in BM staining for the S100 proteins by primary cancer 
(Fisher’s Exact test for S100P p=0.279, S100A4 p=0.135). There were significantly more 
AGR2 positive colorectal and non-small cell lung cancer BMs than expected (p<0.001) but 
fewer OPN positive lung cancer BMs of all types (p=0.033).  Importantly, none of the 
clinical features which are traditionally used to determine prognosis in patients with BMs 
(Gaspar et al., 1997, Sperduto et al., 2008) were associated with positive staining for any of 
the MIPs (summarised in Table 2.4) 
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Figure 2.5: Binary heat map showing the immunohistochemical staining of 138 brain 
metastases removed at neurosurgery for the Metastases-Inducing Proteins osteopontin 
(OPN), S100A4, S100P, anterior gradient 2 (AGR2) and FANCD2. Brain metastases are 
grouped by the primary cancer of origin with red squares showing positive staining of any 
degree (>1% carcinoma cells stained) and green squares indicating negative staining. 
R ZAKARIA - PHD THESIS: LOCAL INVASION IN CEREBRAL METASTASES                              -38-    
 
Table 2.3: Table showing the proportion of brain metastases from different primary cancers 
staining positively (1% or above of cells positively stained to any degree) for each Metastasis 
Inducing Protein.   
Primary cancer 
and number of 
cases 
Osteopontin S100A4 S100P AGR2 
negative positive negative positive negative positive negative positive 
 Breast 4
0 
2% 98% 30% 70% 30% 70% 35% 65% 
Non-small 
cell lung 
3
8 
21% 79% 11% 89% 16% 84% 11% 89% 
Small cell 
lung 
8 50% 50% 62% 38% 62% 38% 50% 50% 
Melanoma 1
6 
6% 94% 19% 81% 25% 75% 81% 19% 
Colorectal 1
2 
0% 100% 42% 58% 17% 83% 0% 100% 
Renal 7 0% 100% 0% 100% 29% 71% 0% 100% 
Oesophagus 5 20% 80% 0% 100% 20% 80% 0% 100% 
Bladder 3 0% 100% 0% 100% 0% 100% 0% 100% 
Squamous 
cell 
2 0% 100% 50% 50% 100% 0% 100% 0% 
Ovarian 2 50% 50% 50% 50% 100% 0% 0% 100% 
Prostate 2 0% 100% 0% 100% 0% 100% 0% 100% 
Endometrial 2 0% 100% 0% 100% 0% 100% 0% 100% 
Pancreas 1 0% 100% 100% 0% 0% 100% 100% 0% 
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Table 2.4: Relation of clinical factors to positive staining for the Metastasis Inducing Proteins 
and cytoplasmic FANCD2 in 138 resected brain metastases cases. 
  
Factor & level 
Osteopontin S100A4 S100P AGR2 FANCD2 
negative positive negative positive negative positive negative positive negative positive 
Metastasis 
location 
Post 
fossa 
9% 91% 18% 82% 36% 64% 18% 82% 76% 24% 
Supra-
tentorial 
12% 88% 25% 75% 23% 77% 30% 70% 84% 16% 
Number of 
metastases 
Multiple 4% 96% 23% 77% 27% 73% 35% 65% 88% 12% 
Solitary 13% 87% 23% 77% 26% 74% 26% 74% 80% 20% 
Synchronous 
presentation 
No 8% 92% 23% 77% 24% 76% 29% 71% 87% 13% 
Yes 20% 80% 24% 76% 32% 68% 24% 76% 71% 29%* 
Controlled 
primary 
No 10% 90% 21% 79% 17% 83% 24% 76% 90% 10% 
Yes 7% 93% 23% 77% 26% 74% 31% 69% 85% 15% 
Extra-cranial 
metastases 
No 14% 86% 22% 78% 25% 75% 23% 77% 78% 22% 
Yes 6% 94% 26% 74% 28% 72% 36% 64% 89% 11% 
Performance 
status  
>70% 11% 89% 24% 76% 26% 74% 33% 67% 86% 14% 
<70% 14% 86% 22% 78% 27% 73% 14% 86%* 70% 30%* 
*indicates significantly different proportion positive:negative staining than expected, 
Fisher’s exact test, 2-sided, p<0.05 
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2.4.3 Association of MIPs with patient outcomes 
Median OS was 7.67 months (95% CI: 4.45 – 10.89) with 10 censored cases and 
only age < 60 years (HR= 0.56, 95% CI: 0.33 - 0.94, p=0.028) was found to be 
independently associated with prolonged OS. There was no relation between positive 
MIP staining and OS (Figure 2.6A & Table 2.5). Amongst patients receiving 
adjuvant WBRT, OS was 3.43 months (95% CI: 1.36 – 5.51) for OPN negative cases 
but 11.20 months (95% CI: 7.68 – 14.72) for positive cases, Log Rank test, p<0.001. 
There was no confounding difference in age (Student’s t-test, p=0.118), performance 
status (p=0.331) nor other clinical factors such as radioresistant tumour types (e.g. 
renal cancer BMs) between the groups to explain this effect. Different cut-offs for 
positive staining were used to check if the percentage of tumour cells staining 
positive related to response to WBRT.  There was a non-significant trend to 
prolonged median OS after WBRT with increasing percentage of positively OPN 
stained tumour cells: 11.2 months if > 5%, 13.9 months if >25% and 15.9 months if 
>50% positively stained.  
Thirty solitary metastases that were completely resected showed intracranial 
progression at a median of 18.9 months from surgery (95% CI: 6.54 – 31.26). Table 
2.6 lists the clinical factors associated significantly with prolonged PFS alongside 
MIP staining. As illustrated in Figure 2.6B, negative staining for S100A4 in the 
resected BM was the only factor independently associated with a longer PFS (HR for 
intracranial progression = 0.17, 95% CI: 0.04 – 0.74, p=0.018). Tumour 
heterogeneity was assessed using different cut-offs for positive staining and there 
was no difference in clinical factors or outcomes when assessing tumours with 
>5%,>25%,or >50% of S100A4 positive staining cells, illustrated for PFS in Figure 
2.6C.  
 
 
R ZAKARIA - PHD THESIS: LOCAL INVASION IN CEREBRAL METASTASES                              -41-    
 
 
 
 
Figure 2.6: (A) Survival of patients with 
and (B,C) disease progression of 138 
brain metastases from different primary 
sites. A. Proportion of patients surviving 
is plotted against overall survival time as  
Kaplan-Meier curves for positive (>1% 
carcinoma cells stained) and negative 
(<1% carcinoma cells stained) 
immunohistochemically stained brain 
metastases for S100A4. Survival time 
was not significantly associated with 
staining for S100A4 (Log rank test, 
p=0.222). B. Proportion of patients 
surviving without intracranial progression 
is plotted against time as Kaplan-Meier 
curves for positive and negative 
immunohistochemically stained brain 
metastasis for S100A4. These patients 
had a grossly resected tumour. Median 
time to progression was significantly 
shorter in cases staining positive for 
S100A4 (11.77 months, 95% CI: 7.07 – 
16.47) versus negatively stained cases 
(27.03 months, 95% CI: 16.49 – 37.57), 
Log Rank test, p=0.007. This effect 
persisted in multivariate Cox analysis 
(HR 0.166, 95% CI: 0.04 – 0.74, 
p=0.018). C. S100A4 positive cases in B 
above are subdivided into categories by 
the proportion of carcinoma cells in the 
specimen staining to various degrees for 
the S100A4 protein (pooled Log-Rank 
test (4 df) = 9.806, p = 0.044). Ticks 
indicate censored data in all panels. 
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Table 2.5: Table showing the overall survival time for patients with a resected brain 
metastasis at different levels of common clinical factors and with positive or negative staining 
for the Metastasis Inducing Proteins and FANCD2. Log rank test statistics for comparison of 
survival (* = p<0.05) are given. 
Factor 
Median overall 
survival/ months  
95% CI 
Log rank & 
significance 
Age 
<60 years 
>60 years 
 
13.0 
3.77 
 
9.16 – 16.84 
2.48 – 5.06 
 
17.549 
p < .005* 
Size of metastasis 
Diameter<30mm 
Diameter>30mm 
 
9.43 
5.37 
 
3.34 – 15.53 
3.44 – 7.30 
 
2.883 
p =.09 
Location of metastasis 
Supratentorial 
Posterior fossa 
 
9.30 
4.90 
 
5.99 – 12.61 
3.05 – 6.80 
 
1.302 
p=.254 
Number of metastases 
Solitary 
Multiple 
 
7.67 
5.77 
 
0 – 15.95 
4.40 – 10.93 
 
0.23 
p=.879 
Synchronous presentation 
Yes 
No 
 
4.93 
9.73 
 
1.55 – 8.31 
5.27 – 14.20 
 
5.627 
p=.018* 
Neurosurgery procedure 
Gross total resection vs. 
Subtotal resection 
 
8.27 
2.93 
 
4.79 – 11.74 
0 – 6.08 
 
9.131 
p=.01* 
Controlled primary disease 
Yes 
No 
 
13.97 
4.53 
 
10.24 – 17.7 
3.84 – 5.22 
 
6.753 
p=.009* 
Extra-cranial metastases 
Present  
Absent 
 
7.67 
6.83 
 
3.11 – 12.22 
2.88 – 10.79 
 
.159 
p=.69 
Performance status 
KPS<70% 
KPS>70% 
 
3.93 
10.83 
 
2.07 – 5.79 
8.32 – 13.35 
 
19.21 
p=.000* 
Adjuvant WBRT  
Yes 
No 
 
9.90 
2.73 
 
7.58 – 12.22 
2.40 – 3.07 
 
20.861 
P<.005* 
Adjuvant chemotherapy 
Yes 
No 
 
18.23 
4.03 
 
13.00 – 23.46 
2.85 – 5.22 
 
28.117 
P<.005* 
Primary  
Breast cancer vs. 
Non-small cell lung cancer 
or melanoma 
 
14.23 
6.43 
5.53 
 
9.21 – 19.26 
3.45 – 9.41 
0 – 16.90 
 
 
9.659 
p=.022* 
S100A4 staining  
Positive 
Negative  
S100P staining  
Positive 
Negative 
AGR2 staining  
Positive 
Negative 
OPN staining  
Positive 
Negative 
FANCD2 cytoplasmic 
staining  
Positive 
Negative 
 
6.83 
9.50 
 
7.40 
8.37 
 
6.83 
9.43 
 
9.30 
3.37 
 
 
6.83 
8.23 
 
5.59 – 13.41 
3.51 – 10.16 
 
3.07 – 11.73 
3.63 – 13.10 
 
3.93 – 9.74 
3.62 – 15.25 
 
6.29 – 12.31 
2.06 – 4.67 
 
 
2.37 – 11.29 
4.94 – 11.52 
 
1.21 
p=.271 
 
1.652 
p=.199 
 
.326 
p=.568 
 
6.861 
p=0.09 
 
 
.012 
p=.912 
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Factor  
(events / total) 
Median PFS / months  
(95% CI) 
Log rank 
comparison & 
significance 
HR (95% CI) & 
significance in Cox 
regression 
Age 
<60 years (26 / 63) 
>60 years (4 / 62) 
 
11.3 (3.49 – 19.1) 
Not reached 
 
4.813, p= 0.028* 
 
0.97 (0.94 – 1.01), 
p=0.059 
Performance status 
KPS>70% (30 / 90) 
KPS<70% (0 / 35) 
 
18.9 (6.54 – 31.26) 
Not reached 
 
3.245, p=0.072 
 
S100A4 staining 
Positive (26 / 97) 
Negative (4 / 28) 
 
S100P staining 
Positive (24 / 95) 
Negative (6 / 30) 
 
AGR2 staining  
Positive (20 / 95) 
Negative (10 / 30) 
 
OPN staining  
Positive (28 / 110) 
Negative (2 / 15) 
 
FANCD2 cytoplasmic 
staining  
Positive (4 / 23) 
Negative (26 / 102) 
 
11.77 (7.07 – 16.47) 
27.03 (16.49 – 37.57) 
 
 
15.2 (6.16 – 24.25) 
24.57 (0 – 49.5) 
 
 
21.77 (10.85 – 32.69) 
11.10 (8.06 – 14.14) 
 
 
19.9 (6.25 – 31.5) 
15.2 (NA) 
 
 
 
21.77 (6.88 – 36.66) 
15.20 (4.96 – 25.44) 
 
7.295, p=0.007* 
 
 
 
0.623, p=0.43 
 
 
 
1.117, p=0.291 
 
 
 
0.035, p=0.851 
 
 
 
 
0.113, p=0.737 
 
0.17 (0.04 – 0.74), 
p=0.018* 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 2.6. Clinical and biological factors associated with prolonged progression free survival 
time from resection to first brain progression. Significant relations highlighted (*). 
 
2.4.4 Subtypes of BMs from common primaries 
Forty patients with breast cancer were assessed separately and staining by subtype of 
breast carcinoma is shown in Table 2.7. The median OS was 14.23 months (95% CI 
9.21 – 19.26) and negative staining for S100A4 was independently associated with 
longer OS (HR for death = 0.26, 95% CI: 0.08 - 0.80, p=0.019, Figure 2.7A) along 
with age <60 years (HR = 0.3, 95% CI: 0.11 - 0.81, p=0.017) and post-operative 
chemotherapy (HR = 0.12, 95% CI: 0.02 – 0.61, p=0.010). As an additional check, 
when the disease specific- graded prognostic assessment (DS-GPA) factors 
(Sperduto et al., 2010) for breast BMs (age, subtype of carcinoma and performance 
status) were combined in a model, the predictive value of staining for the protein 
R ZAKARIA - PHD THESIS: LOCAL INVASION IN CEREBRAL METASTASES                              -44-    
persisted (HR for death in S100A4 negative cases = 0.58, 95% CI: 0.35 - 0.96, p= 
0.033).  Intracranial progression occurred in 15/ 40 breast carcinoma patients and the 
11 / 15 S100A4 positive cases showed significantly earlier intracranial progression 
(median 9.77 months, 95% CI: 8.28 – 11.25) than the 4 /15 negatively stained cases 
(median 27.03 months, 95% CI: 18.46 – 35.60, Log Rank test, p=0.023) (Figure 
2.7B).    
Breast Cancer Osteopontin S100A4 S100P AGR2 FANCD2 
Subtype 
(number) 
negative positive negative positive negative positive negative positive negative positive 
HER2 (18) 0% 100% 22% 78% 22% 78% 17% 83% 89% 11% 
Triple negative 
(12) 
0% 100% 33% 67% 50% 50% 67% 33% 92% 8% 
Luminal (8) 
0% 100% 38% 63% 25% 75% 25% 75% 100% 0% 
Not specified 
(2) 
50% 50% 50% 50% 0% 100% 50% 50% 100% 0% 
 
Table 2.7: Staining of brain metastases for Metastasis Inducing Proteins and FANCD2 in 
patients with primary breast carcinomas by subtype. 
 
 
Figure 2.7: (A) Survival of patients with and (B) disease progression of 40 brain metastases 
from primary breast cancer stained for S100A4. A. Proportion of patients surviving is plotted 
against overall survival time as Kaplan-Meier curves for positive (>1% carcinoma cells 
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stained) and negative (<1% carcinoma cells stained) immunohistochemically stained brain 
metastases for S100A4. Positive staining in the brain metastasis was significantly associated 
with shorter overall survival in multivariate (Cox) analysis (HR of 0.26, 95% CI: 0.08 to 0.80, 
p=0.019) adjusted for age using the average covariate method (Makuch, 1982). B. 
Proportion of patients surviving without intracranial progression is plotted against time to 
intracranial progression as Kaplan-Meier curves for positive and negative 
immunohistochemically stained brain metastases for S100A4. Fifteen out of the 40 
developed intracranial progression and of these, 11/15 cases which were positively stained 
for S100A4 showed significantly earlier progression (median 9.77 months, 95% CI: 8.28 – 
11.25) than the 4 negatively stained cases (median 27.03 months, 95% CI: 18.46 – 35.60, 
Log Rank test, p=0.023). Ticks indicate censored data in all panels. 
 
Non-small cell lung cancer patients had a median OS of 6.43 months (95% CI: 3.45 – 
9.43) and 27 out of 38 received WBRT, this being the only factor associated with 
increased OS (HR of death if WBRT omitted = 3.07, 95% CI: 1.08 – 8.69, p=0.035) 
regardless of incorporating MIP staining or the DS-GPA factors. Only five of 38 
patients developed intracranial progression - reflecting the burden of systemic 
disease on survival in these cases – but notably all of those BMs stained positively 
for S100A4. 
There were 16 malignant melanoma cases and their median OS was 5.53 months 
(95% CI: 0.1 – 16.9). Incorporating the DS-GPA factors (number of BMs and 
performance status) with MIP staining showed that positive staining for S100A4 in 
the BM (13/16 cases) was the only factor independently associated with decreased 
OS (HR for death in negatively stained cases = 0.09, 95% CI:0.01 - 0.97, p=0.047). 
Only 5/ 16 patients developed intracranial progression, and notably all of the S100A4 
positive BMs progressed.  
 
2.4.5 Validation and investigation of intra-tumoural heterogeneity 
Unselected BM samples from 24 prospectively treated patients were analysed, taking 
1% as the cut-off for positive staining; 88% were S100A4 positive and 83% were 
OPN positive. This prospective validation cohort showed no significant differences 
from the retrospective cases in patient age, gender, size of operated metastasis, 
control of systemic disease, extracranial metastases or use of adjuvant chemo- and 
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radiotherapy. 19 / 24 patients received adjuvant WBRT and, as in the retrospective 
series, this conferred a survival advantage in OPN positive (6.3 months if irradiated 
vs 2.7 months if not, Log Rank test, p=0.001) but not in OPN negative cases 
(p=0.08).  In total 9 of 24 cases showed intracranial progression and all of these were 
S100A4 positive (Figure 2.8). In the course of resection additional samples were 
obtained using image guidance at the leading edge of the BMs and all the MIPs 
showed a non-significant trend to a higher percentage of cells positive at the leading 
edge (Wilcoxon matched pairs analysis, p>0.05 for each MIP). S100A4 showed the 
greatest difference between percentage of positively staining cells at the edge and in 
the interior (ratio of 4.3 vs. 1.7 for OPN, 2.5 for AGR2, 3.2 for S100P) although this 
ratio was not associated with any clinical outcome, nor was it related to primary 
tumour type.  
 
Figure 2.8: Kaplan-Meier plots showing time to intracranial progression for prospectively-
analysed brain metastases of patients undergoing resection. All 21 cases with progression 
up to 13 months had stained positively for S100A4 although there was no significant 
difference in survival by the Log rank test (= 1.62, p = 0.203) compared to the 3 negatively 
stained cases. 
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2.4.6 Relationship of S100A4 staining to development of brain metastases 
Given the relation of S100A4 overexpression to progression, the association of 
S100A4 with risk of BMs in patients with known cancer was investigated. In a series 
of breast cancer patients with BMs, 22 / 27 of primary tumours (81%) were S100A4 
positive compared to 18/117 (15%) in a group with known non-metastatic breast 
cancer (Rudland et al., 2000, de Silva Rudland et al., 2011) as shown in Figure 2.9 
(Fisher’s Exact test, p<0.0001). The median time until development of BMs after 
diagnosis of breast cancer was 25.5 months (95% CI: 20.1 – 30.9) and was no shorter 
in the S100A4 positive cases (Log Rank test p=0.67). 
 
 
Figure 2.9: Comparison of staining for S100A4 in non-metastatic and brain metastatic breast 
cancers. The proportion of primary tumours staining positively for S100A4 in a group of 
previously reported patients with non-metastatic breast carcinoma surviving over 20 years 
was found to be significantly different from that of a group of breast carcinoma cases known 
to be brain metastatic (Fisher’s Exact test, p<0.0001). There was no significant increase in 
S100A4 positivity in the breast BMs themselves compared to the primary breast tumours nor 
in the proportion of S100A4 positive staining in BMs from other primaries compared to those 
from primary breast cancer (Fisher’s Exact test, p=0.39, p=0.27 respectively). 
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2.5 Discussion 
 
We have shown for the first time that proteins which are (i) mechanistically proven 
to be involved in extracellular matrix adhesion and cell migration in vitro, (ii) convey 
a metastatic phenotype - including to brain - when overexpressed in animal models 
and (iii) are predictive of clinical outcomes in a variety of solid organ cancer cohorts, 
are also highly expressed at the protein level in human BMs and associate with 
important clinical outcomes. Previous publications have shown that the degree of 
immunohistochemical staining of carcinoma cells for the proteins described, OPN 
(Rudland et al., 2002), S100A4 (Rudland et al., 2000), S100P (Wang et al., 2006), 
AGR2 (Barraclough et al., 2009) and FANCD2 (Rudland et al., 2010) reflect the 
level of each particular protein in the specimens.  
2.5.1 Association of S100A4 with patient outcomes and possible clinical applications  
We found comparable OS to other large, multicentre series of BM patients with age 
and performance status again shown to be strong predictors of outcomes (Sperduto et 
al., 2008, Gaspar et al., 1997).  Additionally, we find that S100A4 was expressed in 
all progressing melanoma and non-small cell lung cancer BMs as well as being 
independently associated with time to intracranial progression in breast cancer - 
where patients had the longest overall survival time - but not in lung cancer, where 
patients were less likely to die from their brain disease. This result holds true even 
when known clinical predictors for each tumor type are incorporated into 
multivariate models (Sperduto et al., 2008) and suggests that S100A4 has some role 
in spreading in the brain microenvironment; in support of this suggestion the protein 
was seen to be expressed at the leading edge of BMs in image-guided samples. It is 
known that S100A4 can reduce the formation of focal adhesions between cellular 
filopodia and the extracellular matrix via myosin heavy chain IIA to cause cell 
migration, invasion and metastasis (Gross et al., 2014) and thus it may represent a 
novel biological marker  or a potential drug target. There is already interest in this 
protein as a monocloncal antibody target in metastatic melanoma and pancreatic 
cancer, following evidence that this family of proteins is a marker of aggressive, 
advanced tumours (Weide et al., 2013) (Hernandez et al., 2013). 
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2.5.2 Relationship of different proteins to BM development 
Although staining for three MIPs is somewhat elevated in these BMs, only that for 
S100A4 show a significant association with clinical outcomes in the form of time to 
intracranial progression in all BMs, and OS in breast cancer and melanoma BMs. 
Since positive staining for S100A4 occurs more often in advanced rather than in 
early breast cancers  in contrast to the other three MIPs (de Silva Rudland et al., 
2011, Winstanley et al., 2013), it may be that only S100A4 plays a role in the 
subsequent progression of those patients with BMs, whilst the other three MIPs 
stimulate earlier and different steps in the metastatic pathways.   
 
2.5.3 OPN as a marker of radiosensitivity 
 
Although WBRT remains a pragmatic and readily available adjuvant treatment for 
BMs, there is concern regarding the cognitive effects in survivors and alternative 
post-operative management strategies are proposed. Using a simple BM marker to 
stratify patients as good or poor radiation responders would therefore be an 
extremely useful clinical tool. Regarding therapeutics, cilengitide, an αvβ3/αvβ5 
integrin inhibitor known to have efficacy in the brain microenvironment, appears to 
enhance radiation response in preclinical breast cancer BM models (Lautenschlaeger 
et al., 2013). It is therefore logical that negative expression of OPN, an αvβ3/αvβ5 
integrin ligand, may predict reduced OS from adjuvant WBRT compared to OPN 
positive cases and this result merits further investigation. 
 
2.5.4 Limitations  
Although retrospective data, particularly for performance status is undesirable, a 
wide range of different tumor types are represented in sufficient numbers to allow 
lung, breast and melanoma to be explored separately and there were no missing data 
fields. To validate either protein as a clinical biomarker, a larger prospective study 
would be required recording tumour and possible also serum IHC levels of S100A4 
and OPN alongside clinical outcomes (Dancey et al., 2010). MRI of asymptomatic 
patients at regular, e.g. 2 monthly follow up, would have captured more detail on 
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intracranial progression, reducing censored data in this category and clarifying if this 
were at the site of surgery, distant or leptomeningeal (an under-recognised 
phenomenon).  
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Chapter 3: MRI markers of local invasion 
3.1 The reliability of routine clinical post processing software in assessing 
potential diffusion weighted MRI biomarkers in brain metastases 
3.1.1 Abstract 
Background & purpose: Diffusion MRI characteristics have been used as biomarkers 
to guide prognosis in cerebral pathologies including brain metastases. The 
measurement of ADC is often described poorly in clinical and research studies, with 
little detail given to the practical considerations of where to place ROIs, which post 
processing software package to use and how reproducible the resulting metrics will 
be. 
Method: We investigated a series of 12 patients with brain metastases and 
preoperative DWI.  Three post processing platforms were used and ROI were placed 
over the tumour, peritumoural region and brain-tumour interface. These recordings 
were made by a neurosurgeon and a neuroradiologist. Inter- and intra-observer 
variability was assessed using Bland-Altman analysis.   
Results: There was excellent correlation between the software packages used for all 
measures including assessing the whole tumour, selective regions with lowest ADC, 
the change of ADC across the brain-tumour interface and the relation of the tumour 
ADC to peritumoural regions and the normal white matter. There was no significant 
inter- or intra-observer variability for repeated readings. There were significant 
differences in the mean values obtained using different methodologies. 
Conclusion: Diffusion weighted MRI metrics offer promise as potential non-invasive 
biomarkers in brain metastases and a variety of metrics have been shown to be 
reliably measured using differing platforms and observers. 
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3.1.2 Introduction  
As discussed in the first chapter, diffusion weighted magnetic resonance imaging 
(DWI) has traditionally been applied to a variety of practical clinical problems 
relating to brain metastases such as differentiation from an intracerebral abscess, but 
more recently parameters such as the tumour ADC have been shown to correlate with 
survival from brain metastases independently of other factors as well as predicting 
grade, invasiveness and survival in a variety of other adult and paediatric brain 
tumours (Berghoff et al., 2013c, Price and Gillard, 2011, Barajas Jr et al., 2010, 
Porto et al., 2013). These metrics have therefore been recommended as "imaging 
biomarkers" which could be integrated with traditional, widely validated tools for 
predicting prognosis and deciding which patients with brain metastases should 
receive treatments such as the recursive partitioning (RPA) or graded prognostic 
assessment (GPA) classifications (Gaspar et al., 1997, Sperduto et al., 2010). If these 
radiological metrics are to be used in routine clinical practice more information is 
urgently needed on how they are practically taken and whether comparable values 
are obtained on different post processing platforms. This information is often lacking 
from studies or, if included, is prohibitively complicated for use outside the research 
setting. Therefore a multidisciplinary group consisting of neurosurgeons, 
neuroradiologists, MR physicist and oncology researchers have retrospectively 
examined a series patients with brain metastases to measure a comprehensive range 
of DWI metrics on different software platforms – including two of the most widely 
available commercial solutions - so that performance and reliability could be 
formally assessed as a prelude to investigation of the diagnostic and prognostic 
impact of DWI in a larger clinical cohort. 
 
3.1.3 Materials and methods 
3.1.3.1 Clinical series 
Twelve patients who had undergone DWI preoperatively followed by resection of a 
brain metastasis were identified from a database of histological samples at our 
institution spanning the period 2007 – 2012. The age at presentation, primary tumour 
type, size of resected lesion, RPA and GPA class of patients are detailed in Table 
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3.1. Of note, 11 of 12 patients had solitary metastases; case #10 had a small 2-3mm 
deposit in addition to the main lesion.  All patients were recorded in the operating 
notes by the surgeon and on post-operative imaging to have undergone gross total 
resection. All patients underwent post-operative whole brain radiotherapy (30 Gray 
in 10 fractions) according to our local protocol and adjuvant chemotherapy for the 
primary tumour in all cases as determined by the treating oncologist.  As seen in 
Table 3.1 half of all cases showed local recurrence, at which point two had further 
treatment (case #1 had stereotactic radiosurgery and case #8 underwent repeat cranial 
surgery) and the remainder were managed palliatively. Eleven patients died and one 
had incomplete follow up. 
Table 3.1: Clinical characteristics and outcomes for 12 patients studied, all of whom 
underwent MR brain including diffusion weighted MRI before surgical resection at a single 
centre. 
 
 
3.1.3.2 Imaging acquisition and analysis 
All patients underwent MRI brain scans on a variety of 1.5T Philips whole body 
systems with single channel head coil at different local institutions before transfer to 
the Regional Neuroscience Centre. The imaging included DW images using one 
acquisition over 90 seconds through single-shot echo planar imaging with 2 b values 
of 0 and 1000 second/mm
2
  in all cases as well as other sequences, as determined by 
the local institution’s protocol.  MR parameters differed between institutions, but 
were in the following range:  slice thickness 6mm for all, TR 2515 - 3513 msec, TE 
71-94 msec; FOV 128x128mm (n=5) or 256x256mm (n=7). Isotropic DW maps and 
ADC maps were calculated and subsequent readings taken using three different post 
processing software packages: GE FuncTool version 4.5.5 (General Electric Co., 
Maryland, USA), Philips Extended MR workspace (EWS) version 2.6.3.1 (Philips 
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Medical Systems, Netherlands) and DTI Studio version 3.0.3 (H Jiang & S Mori, 
Johns Hopkins University, Baltimore, USA) running on a Windows platform. The 
first observer, a clinical research fellow in neurosurgery with no higher radiological 
training took the readings described below and shown in Figure 3.1. A second 
observer with 10 years specialised training in neuroradiology took repeat readings of 
all metrics for all patients. Before any analysis of results, at a delay of 6-8 weeks 
from initial recording, the first observer then took repeat observations on the same 
platform of all metrics for all patients.  
Figure 3.1 demonstrates the position of regions of interest (ROI) for recording each 
metric: 
 Whole tumour ADC: The axial slice with the largest area of tumour is 
identified and a freehand ROI is created using the tumour border. Average 
values were obtained and repeated on the slices immediately above and below 
using the same method, the mean of the three being the “whole tumour 
ADC”. This method generates a maximum and minimum reading for the 
given ROI and the minimum ADC was also recorded and averaged over 3 
slices, to give the ADCmin. 
 ADCmean: Next an alternative method for taking the ADC within each 
tumour was ascertained by placing as many 50mm
2
 regions of interest (ROI) 
as could be accommodated within the borders of the tumour on each axial 
slice, avoiding areas of cyst, necrosis or haemorrhage, and taking the mean 
(the ADCmean). Cases with extensive (>25%) haemorrhage were excluded as 
diffusion analysis would have been meaningless. Up to four control readings 
were also taken from the unaffected contralateral white matter so that 
ADCmean values could be adjusted to this (ADC normalised). 
 Peri-tumoural region: Readings (up to 3 on contiguous slices) of the near 
and far peritumoural region were taken, defining the "peri-tumoural region" 
as the extent of signal abnormality on the T2-weighted sequence and "near" 
as <1cm from the tumour edge. 
 ATC: Finally to assess the tumour-brain interface, the gradient of change of 
the ADC across the tumour edge and into brain, the "ADC Transition 
Coefficient" or ATC was calculated as previously described (9).   
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Figure 3.1: Method of recording metrics for use as potential biomarkers from an ADC map.  
A. T2 weighted MRI brain showing a solitary occipital mass and surrounding oedema in a 
patient with known breast cancer presenting with headache & visual disturbance.  
B. The lesion shows enhancement with an area of central lower signal, possibly necrosis, on 
T1 weighted sequence after administration of gadolinium contrast medium.  
C. Diffusion weighted image of the same slice showing the mean of three gradients at 
B=1000.  
D. This is used to generate an ADC map as described and the whole tumour is encircled 
with a freehand region of interest (ROI) to record the "whole tumour ADC" and minimum 
ADC (ADCmin) of the lesion.  
E. Multiple ROI are placed inside the tumour avoiding cystic, necrotic and haemorrhagic 
areas and the values averaged to give the ADCmean.  
F. Regions of interest are placed across the brain-tumour boundary and the gradient of 
change of ADC calculated in up to 3 directions on up to 3 slices and the mean taken to yield 
the ADC transition coefficient, or ATC. 
 
3.1.3.3 Statistical methods 
Data were analysed and graphs generated using standard methods on Statistica 
version 6 (StatSoft, Inc. 2003) and GraphPad Prism version 6.02 (GraphPad 
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Software, California USA).  The level of significance was set at 95% to reject the 
null hypothesis and all p-values are stated in Results. Intra-class correlation 
coefficients were plotted to determine if readings for a given metric but different 
platforms were from the same population and individual r values for each 
comparison are listed. Bland-Altman plots of the mean versus the difference for 
intra- and inter- observer reliability comparisons are shown with confidence intervals 
(95%) or bias is shown in tables. Group means for each metric are compared with 
student t-tests and tests for normality and variance stated where applied.  
 
3.1.4 Results 
3.1.4.1 Measures of tumour ADC 
Whole tumour ADC varied between 0.68 and 1.307 10
-3
 mm
2
 /s with values for each 
individual case are shown in Figure 3.2 along with measures of correlation between 
the three platforms and Bland-Altman analysis for both intra- and inter-observer 
reliability. This method, which used a single freehand ROI drawn around the whole 
tumour, produced consistent readings across platforms and observers. The same 
analysis was applied to the ADCmin, ADCmean and normalised ADC metrics with 
similar agreement between platforms (shown in Table 3.2) and between observers 
(Table 3.3). Finally the different measures of tumour ADC (whole tumour ADC, 
ADCmin & ADCmean) were compared to one another. Significant differences were 
found between the group means for each metric, as shown in Figure 3.3, despite a 
strong correlation between whole tumour ADC and ADCmean (r=0.8855, p<0.05). 
The normalised ADC is a ratio of ADCmean to contralateral white matter and has no 
units but showed significant correlation with both ADCmean (r=0.98, p<0.01) and 
whole tumour ADC (r=.8746, p<0.05).  
R ZAKARIA - PHD THESIS: LOCAL INVASION IN CEREBRAL METASTASES                              -57-    
 
Figure 3.2: Analysing a metric as a potential biomarker. Three different post processing 
platforms are used to construct an ADC map from baseline DWI sequences and take 
readings. 
A. Whole tumour ADC readings using Philips EWS and DTI studio software are plotted 
against those taken on the GE FuncTool software and Pearson correlation coefficients 
calculated, indicating  highly significant correlation with r = 0.82 (P<0.01, 95% CI: 0.48 – 
0.95) for Philips EWS vs. GE FuncTool and r = 0.96 (P<0.01, 95% CI: 0.89 – 0.99) for 
DTIstudio vs. GE FuncTool.  
B. Bland-Altman plots of mean and difference of whole tumour ADC readings for a second 
observer with the 95% confidence intervals and the mean (bias) shown.  
C. The same analysis is conducted for repeat readings taken by the original observer, 
indicating again that there is good agreement with all points within the 95% confidence 
intervals shown in dashed lines. 
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Table 3.2: Starting with the same DWI base data, each metric was derived using three 
different software packages for each of 12 cases and the readings compared. All relations 
were highly significant with F test compared to True Value 0, p<0.05, ADC = apparent 
diffusion coefficient, ATC = ADC transition coefficient 
 
 
 
Table 3.3: Bland-Altman analysis was performed on pairs of readings for each metric to 
investigate the variation between the same observer and between two independent 
observers. Bias (the mean difference) and confidence intervals are shown for each metric 
and each comparison. 
 
Figure 3.3: The 
ADC values for 
the 12 cases are 
demonstrated, as 
measured by 3 
different methods. 
The whole tumour 
ADC is derived by 
drawing a single 
freehand region of 
interest around 
the tumour border 
on the axial slice 
with the largest 
area and 
repeating for the 
slices above and 
below. The 
ADCmin is the 
lowest value 
recorded within 
this region. The 
ADCmean is obtained by placing multiple (up to 4) regions of interest of 50mm
2
 within the 
tumour avoiding cystic, haemorrhagic and necrotic regions. The ** indicates highly significant 
differences as assessed by the student t-test for dependent samples, with p < 0.01. 
 Intraclass correlation coefficient 
Reading 
GE Functool vs. 
DTI studio 
GE Functool vs. 
Philips EWS 
DTI studio vs. 
Philips EWS 
Whole tumour ADC 0.986 0.945 0.968 
ADC mean  0.964 0.973 0.954 
ADC min  0.943 0.963 0.958 
ATC  0.870 0.909 0.736 
Normalised ADC  0.968 0.949 0.968 
Near peritumoural ratio  0.938 0.912 0.846 
Far peritumoural ratio  0.815 0.807 0.717 
R ZAKARIA - PHD THESIS: LOCAL INVASION IN CEREBRAL METASTASES                              -59-    
3.1.4.2 Assessment of the peritumoural region and brain-tumour interface 
The ATC measured the rate of change of ADC across the interface from tumour into 
brain and was reliably measured by all three platforms, with correlations shown in 
table 3.2. It was noted that the correlation was not as strong as for other metrics 
which were directly measured rather than derived but nonetheless still significant. 
Ratios of the tumour to the near and far peritumoural region may reflect the intensity 
of surrounding peritumoural oedema and these measures were reliably measured by 
all three platforms with high intra- and inter-observer reliability as indicated in 
tables 3.2 & 3.3. The ratio of the far peritumoural region:tumour was significantly 
higher than that of the near region:tumour ratio for the group (t-test for dependent 
samples = 2.37, p <.05 having confirmed that both samples were normally 
distributed). 
 
3.1.5. Discussion 
3.1.5.1 Main findings and implications 
The measurement of ADC is often described poorly in clinical and research studies, 
with little regard given to the practical considerations of where to place regions of 
interest, which post processing software package to use and how reproducible the 
resulting metrics will be. We have shown that using three widely available platforms, 
a number of metrics can be derived from DWI with minimal inter- and intra-observer 
variability and good agreement between software packages.  
The way in which these metrics are taken (average readings, whole tumour readings, 
and minimum readings) does have an impact, as although the trends within the group 
correlated for each measure, the means obtained differ significantly in a given case.  
For example, we found lower mean ADC readings obtained when placing multiple 
ROI as compared to drawing a freehand ROI around the whole tumour outline, 
because the latter samples the central necrotic area of the mass in many cases (as 
demonstrated in Figure 3.1).  Likewise we found no value in normalising to white 
matter per se in this case, although this is widely described in the literature and 
seems scientifically justified. This implies more clear definition of what method is 
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being used to measure "tumour ADC" and why, is required in studies reported in the 
literature.  
 
3.1.5.2 Relation to existing studies of similar nature 
Other researchers have examined the DWI characteristics of brain metastases. A 
study assessing the incidence of restricted diffusion in brain metastases of various 
primaries found similar readings to ours using a method of placing ROIs on the solid 
part of the tumour with the lowest ADC signal (Berghoff et al., 2013c). The authors 
could not find a relationship between histopathology and the ADC values in cases of 
restricted diffusion. Another retrospective series took ADC readings by averaging 
multiple ROI within tumour and found a similar range to ours (median 0.969 x 10
-3
 
mm
2
 /s) in 32 patients but also an association of higher ADC with prolonged overall 
survival (Duygulu et al., 2010). A further study compared the post-operative 
histology to preoperative DWI readings and found a correlation of various measures 
of ADC with cellularity but not specific primaries for a group of 13 operated cases 
(Hayashida et al., 2006). All these studies employed different methods to measure 
"tumour ADC" with little detailed explanation as to the rationale, exact methodology 
or post processing software used. Recent evidence supports the notion that small 
differences in methodology may cause variations in diffusion-based (ADC, 
tractography) metrics for healthy individuals (Bilgili and Unal, 2004, Urger et al., 
2013, Ozturk et al., 2008) and there has been recent discussion about the 
reproducibility of perfusion MR parameters (Heye et al., 2013, Goh et al., 2013).  
 
Other specialities which are utilising DWI metrics as biomarkers have begun to 
address these practical considerations. ADC readings from liver lesions in 48 patients 
taken using a "PACS" desktop system were compared with Philips and Siemens MR 
workstations to show there were no significant differences and the authors concluded 
that this should allow wider dissemination and use of such readings in patient care 
(El Kady et al., 2011). For colorectal cancer, the effects of ROI size and placement 
on reliability has been investigated, as well as the important question of how these 
metrics change in a given patient or tumour over time and during therapy (Lambregts 
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et al., 2011b). It has been shown that for healthy volunteers variations in voxel size 
do not affect ADC values (Oouchi et al., 2007). 
 
3.1.5.3 Limitations 
In order to determine whether the values obtained are inherent to the lesion, one 
would have imaged the same patient on different MRI machines (for example GE 
and Philips or 1.5T and 3T) and processed the baseline diffusion weighted sequences 
on both sets of software. In practice patients are at a late stage in systemic cancer 
treatment and are undergoing a second scan in order to obtain anatomical, fine cut 
sequences for use on image guidance software packages for surgical planning. A 
further MRI scan preoperatively simply to compare the platforms is unlikely to be 
ethically justifiable or acceptable to patients and this is, therefore, the best type of 
comparison one may be able to make. Patients were taking dexamethasone at the 
time of MRI scan and surgery so any effect on tumour or peritumoural regions 
should be comparable.  
 
3.1.6 Conclusions 
Diffusion weighted MRI may potentially provide non-invasive and widely available 
biomarkers of invasion and survival in brain metastases. This study confirms that 
reliable measurements can be obtained on clinically available software packages with 
minimal intra- and inter-observer variability. However, careful definition of how 
regions of interest are placed and what is being measured are needed in order to 
move forward.  
 
3.1.7 Further study 
Having shown that diffusion MRI measurements can be reliably taken using clinical 
data and platforms and investigated the methodology, a larger study was conducted 
to investigate the relation of these measurements to clinical outcomes in brain 
metastasis patients.  
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3.2 Diffusion weighted MRI characteristics of the cerebral metastasis to brain 
boundary predicts patient outcomes 
3.2.1 Abstract 
Background: Diffusion MRI has been used in neurological and neurosurgical 
practice mainly to distinguish cerebral metastases from abscess and glioma. There is 
evidence from other organs and disciplines that diffusion MRI may be used as a 
biomarker in various conditions. We therefore investigated diffusion weighted MRI 
characteristics of cerebral metastases and their peritumoural region recorded pre-
operatively and related these to patient outcomes.  
Methods: Retrospective analysis of data from 76 cases operated upon at a single 
institution. Diffusion weighted MRI was performed pre-operatively at 1.5T and maps 
of apparent diffusion coefficient (ADC) generated using standard protocols. 
Readings were taken from the tumour, peritumoural region, across the brain-tumour 
interface and in normal white matter. Patient outcomes were overall survival and 
time to local recurrence.  
Results: Metastases from different primary cancers appeared to have different 
diffusion characteristics. These diffusion characteristics were strongly related to the 
cellularity of the metastases in a sample of cases that were analysed histologically. 
Patients having a metastasis with a higher ADC value preoperatively tended to 
survive longer and have better local control rates after surgery regardless of adjuvant 
therapies. This was not simply due to differences between the types of primary 
cancer, because the effect was observed even in a subgroup of 36 patients with the 
same primary, non-small cell lung cancer. For metastases of certain primary cancers, 
diffusion appeared to vary between near and far peritumoural regions, but these 
differences were not associated with patient outcomes. The change in diffusion 
across the tumour border and into peritumoural brain was more strongly predictive 
than ADC readings alone and metastases with a sharp change in diffusion across this 
border (measured by the “ADC transition coefficient” or ATC) had a significantly 
shorter overall survival and shorter time to local recurrence compared to those with a 
more diffuse edge. The ATC was the only imaging measurement which 
independently predicted overall survival in multivariate analysis suggesting this is a 
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powerful predictive measure even in a heterogeneous disease such as brain 
metastases.  
Conclusions: Diffusion weighted MRI demonstrates changes in the tumour, across 
the tumour edge and in the peritumoural region which may not be visible on 
conventional MRI and this may be useful in predicting patient outcomes for cerebral 
metastases.  
 
3.2.2 Background 
As described in Chapter 1, when comparing cerebral metastases to glioma 
considerable attention has focused on the peritumoural region around the lesion 
(Wang et al., 2009, Tsuchiya et al., 2005, Toh et al., 2011, Stadnik et al., 2001, Lu et 
al., 2004, Lee et al., 2011, Chen et al., 2012b, Byrnes et al., 2011). A number of 
metrics from DWI including ADC values have been directly measured in this region 
and the “normal” range of values for a metastasis determined (Sternberg et al., 2013). 
The interaction of cerebral metastases and the surrounding brain tissue would be 
expected to be crucial to the development of therapies aimed at preventing further 
spread and invasion. Work on different methods of invasion - either co-opting 
existing blood vessels or inducing new blood vessel formation - has already led to 
anti-angiogenesis drugs for certain cerebral metastases (Kienast et al., 2010, 
Leenders et al., 2004). Furthermore, the degree of invasion of metastases may affect 
the margin used in existing treatments such as surgery and radiosurgery. Despite this 
potential clinical importance little has been done to investigate the invasiveness of 
cerebral metastases using MRI and nobody has compared the tumor and peritumoural 
ADC readings within a group of metastases. We therefore examined the MRI 
characteristics of the tumor, tumor boundary and peritumoural region for a series of 
patients with cerebral metastases who had undergone pre-operative MRI with DWI 
followed by surgery. We investigate whether patient outcomes such as survival and 
recurrence may be predicted by different DWI metrics.  
 
3.2.3 Materials and methods 
3.2.3.1 Patients 
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Patients with a diagnosis of cerebral metastasis were identified from a histopathology 
archive spanning the period 2007 – 2012 at a single institution. Records were 
searched and cases with a diffusion weighted MRI scan of the brain prior to first 
neurosurgical intervention were selected. Post-operative clinical course and oncology 
care including administration of whole brain radiotherapy (WBRT) or the use of 
adjuvant systemic chemotherapy were recorded from tumour board and patient notes 
as these were potential confounding factors. This study was conducted in accordance 
with the principles of the declaration of Helsinki. Ethical approval was granted as an 
internal project within the institution’s research tissue bank (National Research 
Ethics Service # 11/WNo03/2) for which patients have to give written informed 
consent for inclusion.  
 
3.2.3.2 Histological analysis 
All cases had been reviewed by a consultant neuropathologist in the course of routine 
clinical care. A histological diagnosis of metastasis was made and primary tumour 
type suggested by review of H&E sections, tumour specific immuno-histo-
cytochemistry and clinical correlation. Where original material was available an 
additional automated assessment of cellularity was then made “blind” to the clinical 
and imaging data. Five separate 200x magnification fields were photographed 
avoiding gross haemorrhage or necrotic material on the H&E slide. Using Image J 
software (U. S. National Institutes of Health, Bethesda, Maryland, USA 2007-2012) 
with no additional plugins the percentage area occupied by nucleus versus cytoplasm 
was determined using the measure function. A second independent observer, a 
cellular pathology researcher of 30 years’ experience then repeated this analysis 
using a grid and microscopy alone. 
 
3.2.3.3 Image analysis 
MRI parameters and methodology have been described in Section 3.1. A number of 
different assessments of diffusion were made for each metastasis from the DWI scan 
and resulting ADC map and these are summarised once again in Figure 3.4. 
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Figure 3.4: Measurement of ADC metrics from brain metastases on diffusion MRI scans. A 
patient with a history of lung adenocarcinoma presents with headache and focal neurological 
deficit. A. T1 weighted MRI with gadolinium demonstrates a right frontal lesion, which was 
confirmed as a metastasis after excision. B. An ADC map is generated from B=0,1000 
images using post processing software. On this colour map, blue areas represent low ADC 
and red higher ADC. C. A freehand region of interest is traced around the tumour border 
using the T1+gadolinium scan as reference on the axial slice with the largest tumour area 
and those immediately above and below. The ADCmin is the lowest bin of a histogram of 
ADC values for all pixels contained within this ROI, averaged over these three slices. Three 
ROI are placed within the tumour on the axial slice with the largest area, avoiding necrosis, 
haemorrhage, cyst and the mean taken to give ADCmean. D. To assess change of ADC 
across the tumour border, four ROI are placed starting just inside the tumour border and 
extending out into the peritumoural region. The slope of the four ADC values is taken as the 
“ADC transition coefficient” or ATC. This is repeated in 3 orthogonal directions, avoiding 
structures such as ventricle or falx and then repeated on two slices above and below, with 
the ATC being the mean of the 9 readings. 
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3.2.3.4 Follow up & statistical methods 
Patients were followed up in regional oncology clinics and repeat MRI brain taken 
only if symptoms were present. Local recurrence or progression was defined as 
demonstrable brain disease on a post-operative MRI with appropriate clinical 
correlation and management; patients dying before that point were censored at the 
last clear brain scan (CT or MRI) or last clinical appointment when neurologically 
well. Patients who could not be confirmed deceased were censored at the last clinic 
appointment that had been recorded. 
Data were analysed and graphs generated using Statistica version 6 (StatSoft, Inc. 
2003) and SPSS version 20.0 (IBM co., 2011). For analysis of survival, the Kaplan-
Meier product limit method was used and life tables with survival curves plotted. 
Log rank tests were applied to detect differences between paired groups and 
Wilcoxon modification (the Breslow Chi square test) used in cases where hazard did 
not appear to be proportional. For multivariate analysis Cox regression was used. 
Standard tests were used for comparisons of means and analysis of variance and 
descriptive statistics, distributions were plotted for all variables to check 
assumptions. The level of significance was set at 95% to reject the null hypothesis 
and all p-values and confidence intervals are stated.  
 
3.2.4 Results & Discussion 
3.2.4.1 Clinical outcomes 
The demographic details of the cohort of 76 patients are summarised in Table 3.4. 
The median survival from first diagnosis of cerebral metastasis to death was 9.3 
months (range 0.9 – 34.3 months). 11 cases were censored, mainly due to death by 
other causes or loss of follow up suggesting the length of the follow up period was 
adequate. It was not appropriate to analyse local recurrence where the tumour was 
not fully resected; in the 66 cases where gross total resection was performed, local 
recurrence occurred in 16 patients (24%) at a median of 17.7 months from 
presentation (95% CI 10.9 – 24.6). The factors associated with overall and 
progression free survival, including standard MRI measures such as tumour size, 
volume and number, are summarised in Table 3.5. 
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Age at diagnosis / years 
(mean & range) 
60.6 (35.9 – 81.4)  
Gender 
36 male : 40 
female 
 
Disease information number % 
Primary cancer type 
Non-small cell lung 
Small cell lung 
Breast 
Melanoma 
Gastrointestinal 
Urogenital 
Ovarian 
Squamous cell tonsil 
Unknown primary 
 
36 
6 
10 
5 
5 
4 
4 
1 
5 
 
47.4 
7.9 
13.7 
6.6 
6.6 
5.3 
5.3 
1.3 
6.6 
Size of operated lesion 
(median & range) 
27 (9 – 70) 
8.9 (0.3 – 130) 
Diameter / mm 
Volume / cc 
Location operated lesion 
Supratentorial 
Infratentorial 
 
64 
12 
 
84.2 
15.8 
Number of brain mets 
Solitary 
2 lesions 
>2 lesions 
 
56 
11 
9 
 
73.7 
14.5 
11.8 
RPA class 
I 
II 
III 
 
19 
51 
6 
 
25 
67.1 
7.9 
GPA score 
<1.0 
1.5-2 
2.5-3.0 
>3.0 
 
6 
20 
39 
11 
 
7.9 
26.3 
51.3 
14.5 
Neurosurgery 
Gross total resection 
Partial resection / Biopsy 
 
67 
9 
 
88.2 
11.8 
Adjuvant chemotherapy 
for systemic cancer 
 
45 
 
59.2 
Adjuvant whole brain 
radiotherapy 
 
 
56 
 
73.7 
 
Table 3.4: Demographics and treatment summary for the series (76 patients) 
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Factor 
Overall 
survival 
Median / 
months 
 
95% CI 
Sig. on 
univariate 
analysis 
Progression 
free survival 
Median / 
months 
 
95% CI 
Sig. on 
univariate 
analysis 
GPA score                         
<1.0 
1.5-2 
2.5-3.0 
>3.0 
5.3 
6.8 
9.3 
9.8 
0.4 – 10.2 
0 – 14.0 
8.0 – 10.6 
7.8 – 11.7 
0.306 
not reached 
18.4 
17.8 
13.1 
 
- 
6.1 – 29.4 
9.0 – 17.2 
0.936 
RPA class                          
I 
II 
III 
14.0 
8.4 
2.0 
 
6.1 – 22.0 
5.1 – 11.8 
0 – 6.2 
0.030* 
 
17.7 
13.1 
not reached 
14.6 – 20.9 
9.7 – 16.6 
0.636 
Primary cancer 
Lung non-small cell 
Lung small cell 
Breast 
Colorectal 
Melanoma 
Urological 
Ovarian 
Unknown 
 
9.2 
4.5 
10.4 
6.8 
11.5 
4.0 
11.2 
5.6 
 
2.0 – 19.8 
1.0 – 28.9 
0.9 – 21.2 
5.3 – 12.3 
2.4 – 14.7 
1.1 – 9.6 
4.7 – 30 
1.5 – 22.8 
 
0.061 
 
 
not reached 
10.5 
9.2 
not reached 
7.3 
not reached 
17.8 
18.4 
 
 
- 
5.6 – 12.9 
 
4.9 – 9.7 
 
- 
- 
(too many 
censored 
in each 
category 
cases for 
analysis) 
Location 
Supratentorial 
Infratentorial 
 
9.6 
4.4 
 
8.2 – 11.1 
0 – 10.1 
 
0.070 
 
17.7 
not reached 
10.8 – 24.6 
 
0.872 
Surgery                   
Biopsy 
Resection 
5.9 
9.6 
0 – 16.4 
8.1 – 11.0 
0.091  
  
 
Adjuvant WBRT 
Yes 
No 
 
10.5 
2.4 
 
8.9 - 12 
1.5 – 3.3 
 
0.000* 
 
17.7 
not reached 
10.9 – 24.6 
 
0.000* 
Adjuvant chemo 
Yes 
no 
 
10.5 
5.3 
 
8.2 – 12.7 
3.0 – 7.6 
 
0.001* 
 
15.7 
not reached 
10.7 – 20.6 
 
0.240 
DWI metrics 
ADCmin>919  
x10
-6
mm
2
/s 
ADCmin<919  
x10
-6
mm
2
/s 
 
ADCmean>1148 
x10
-6
mm
2
/s 
ADCmean<1148 
x10
-6
mm
2
/s 
 
ATC>0.279 
ATC<0.279 
 
9.7 
 
6.2 
 
 
9.7 
 
6.7 
 
 
6.8 
11.2 
 
8.5 – 11.0 
 
3.7 – 8.8 
 
 
7.9 – 11.5 
 
4.9 – 8.5 
 
 
5.3 – 8.4 
8.3 – 14.0 
 
 
0.049* 
 
 
 
 
0.093 
 
 
 
 
0.041* 
 
18.4 
 
11.3 
 
 
18.4 
 
11.3 
 
 
11.3 
not reached 
 
13.2 – 23.6 
 
8.4 – 14.3 
 
 
11.6 – 25.1 
 
5.8 – 16.8 
 
 
8.2 – 14.4 
 
 
0.087 
 
 
 
 
0.039* 
 
 
 
0.072 
 
MRI metrics 
diameter>30mm 
diameter<30mm 
 
volume > 8.9 cc 
volume <8.9 cc 
 
Solitary 
2 lesions 
>2 lesions 
 
6.7 
9.6 
 
6.7 
9.6 
 
8.42 
14.1 
6.1 
 
2.4 – 11.0 
8.8 – 10.4 
 
1.9 – 11.5 
8.8 – 10.3 
 
5.3 – 11.5 
10.7- 17.6 
5.1 – 12.2 
 
0.246 
 
 
0.077 
 
 
0.101 
 
13.1 
17.8 
 
13.1 
17.8 
 
15.7 
11.3 
not reached 
9.7 – 16.6 
14.7 – 20.1 
 
9.2 – 17.1 
13.7 – 21.8 
 
10.3 – 21.0 
0.85 – 21.8 
 
0.551 
 
 
0.158 
 
 
0.673 
Table 3.5: Which factors were associated with survival and progression? 
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3.2.4.2 ADC readings from the metastases & tumour cellularity 
The median ADCmean for cerebral metastases in this series was 1148.1 x 10
-6
mm
2
/s 
and the median ADCmin was 919.4 x 10
-6
mm
2
/s. There were significant differences 
in ADC between cerebral metastases from different primary cancers by one-way 
ANOVA (F=2.797, p=0.025). On post hoc comparison, this was seen to be because 
metastases from the so-called “poorly differentiated” cancers such as melanoma 
(n=5) and small cell lung carcinoma (n=6) had a lower ADC compared to the 
metastases from carcinomas such as breast (n=10), ovarian (n=4) and colorectal 
(n=4), as shown in Figure 3.5. 
 
Figure 3.5: ADC values of 76 brain metastases by primary cancer of origin. The mean 
ADCmin value for each primary cancer type is shown +/- standard error and * indicates 
significant difference from the group at p<0.05 by independent student t-test. All histological 
diagnoses were confirmed by neuropathology assessment after biopsy or resection and 
correlation with clinical data. 
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Tissue was only available for 16 of 76 cases. Cellularity assessment by ImageJ 
software as compared to pathologist assessment appeared to be valid with 
consistency between the two observers (intraclass correlation coefficient= 0.61, 
p<0.05). The mean cellularity was negatively correlated with both the ADCmin and 
the ADCmean and could be fitted to either of these with a simple linear regression 
model which was highly significant (for ADCmin, F = 7.99, p=0.013 and for 
ADCmean F=5.56, p=0.033). ATC was strongly correlated with cellularity as shown 
in Figure 3.6 and was predicted by it using a simple linear regression model 
(F=9.84, p=0.007). 
 
Figure 3.6: The gradient in change of ADC across the tumour border on preoperative 
DWI for brain metastases, called the ATC (see Methods) was strongly predictive of the 
cellularity, as shown in the scatterplot above. Cellularity was assessed in a semi-
automated fashion using ImageJ software from five different high power fields and ATC 
measured as shown in Figure 3.6. The line shows a simple linear regression model 
which was highly significant (ATC = 0.007* mean cellularity + 0.07, ANOVA F=9.84, 
p<0.001). 
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3.2.4.3 Relation of tumour ADC to patient outcomes 
For survival analysis, the patients were grouped based on each of the diffusion 
characteristics of their cerebral metastases and the two groups compared. The cases 
having a higher than median ADCmin (>919.4 x 10
-6
mm
2
/s) showed a longer overall 
survival, median 9.7 months (95% CI: 8.5 – 11.0) versus those with a lower ADCmin 
(median survival 6.2 months, 95% CI: 3.7 – 8.8, Breslow Chi square 3.87, p=0.049). 
There was no difference in the proportion of patients receiving WBRT in the high 
versus the low ADCmin groups that would confound the effect on survival (Chi 
square = 3.49, p =0.062). The effect was also seen if the median ADCmean was used 
as the cut-off to define the two groups but was not statistically significant: OS 9.7 
months, 95% CI 7.9 – 11.5 for patients with metastases having a higher ADCmean 
(>1148.1 x 10
-6
mm
2
/s) versus 6.7months for lower ADCmean, 95% CI 4.9 – 8.5, 
Breslow Chi square = 2.83, p = 0.093.  
 
Regarding local control, the median progression free survival was 11.3 months (95% 
5.8 – 16.8) in those cases with a low ADCmean reading versus 18.4 months (95% CI 
11.6 – 25.1) in those with a high ADCmean (Log rank test, Chi Square 4.263, 
p=0.039). This is illustrated in Figure 3.7. This effect was also seen when the 
median ADCmin was used as the cut-off to define the two groups but did not reach 
statistical significance  (high ADCmin, progression free survival 18.4 months, 95% 
CI 13.2 – 23.6 versus low ADCmin, progression free survival 11.3 months, 95% CI 
8.4 – 14.3, Log rank = 2.93, p = 0.087).  
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Non-small cell lung cancer metastases represented the largest group of cases from a 
single primary cancer (although this group also has subdivisions, predominantly 
these were adenocarcinoma cases and they are at least more uniform than any 
previous analysis which includes multiple different primary sites) and this subgroup 
of 36 cases was therefore analysed separately in order to confirm that the ADC has 
value in and of itself as a prognostic marker not simply as a surrogate of the primary 
tumour type. Overall survival was significantly longer for non-small cell lung cancer 
cases with a high tumour ADCmin at 9.7 months (CI 6.7 – 12.6) versus 5.3 months 
(CI 2.2 – 8.5) for those with low ADCmin, Log rank Chi square = 4.008, p=0.045. 
The same effect was observed and was significant using median ADCmean as the 
cut-off because higher ADC group had median OS 10.5months (CI 7.7 – 13.2) versus 
5.8 months, (CI 3.2 – 8.4) for low ADC group, Log rank=4.135, p = 0.042.  
 
3.2.4.4 ADC changes at the brain-metastasis interface  
The change in diffusion across the brain-metastasis interface might be expected to 
reflect to changes at the cellular level and hence even reflect tumour-stroma 
interactions. We devised and applied a measure of the changing ADC at the 
metastasis-brain boundary, called the ADC transition coefficient or ATC. This could 
be calculated for 70 cases (as described in the methods there needs to be a boundary 
to surrounding tissue to measure and calculate a reading) and found the ATC to have 
a median value of 0.279 (range 0.063 - 0.453). The ATC showed no relationship to 
the primary cancer type on one-way ANOVA (df=11, F=0.348, p=0.9) and weak 
negative correlation with ADCmean and ADCmin (Pearson correlation coefficient -
0.39 and -0.33 respectively, p>0.05) suggesting it was measuring some novel feature 
rather than just acting as a surrogate of the other ADC characteristics or the primary 
cancer.  
 
The group was divided into two based on the ATC, and those patients with a 
metastasis showing high ATC (> median) and therefore a sharp boundary on the 
ADC map had a shorter overall survival 6.8 months (95% CI 5.3 – 8.4) as compared 
to those with a low ATC and hence diffuse boundary on ADC map (11.2 months, 
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95% CI 8.3 – 14.0, Log rank Chi-Square = 4.19, p=0.041). This is illustrated more 
clearly in the conventional MRI scans and accompanying ADC maps in Figure 3.8. 
There was also a tendency to earlier local recurrence in high ATC cases versus low 
ATC but this was not statistically significant (shown in Table 3.5). 
 
 
Panel C. These metastases differ in their outcomes and the cases with a high ATC (> 
median) and therefore a sharp boundary had a shorter overall survival 6.8 months (95% CI 
5.3 – 8.4) as compared to those with a low ATC and hence diffuse boundary (11.2 months, 
95% CI 8.3 – 14.0, Log rank Chi-Square = 4.19, p=0.041). This effect was significant even in 
multivariate analysis. 
Figure 3.8: Panel A. 
demonstrates a lesion with a high 
ATC or “ADC transition 
coefficient” implying a sharp 
border. This type of metastasis 
tended to have a high cellularity 
(H&E section x200). Panel B. 
demonstrates a case which looks 
superficially similar on T1 
weighted sequence with 
gadolinium but actually has a 
much more diffuse border on the 
ADC map and hence a low ATC, 
with lower cellularity.  
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3.2.4.5 ADC readings in the peritumoural region 
Initially we did not find a large variability in the ADC around a given metastasis and 
for the 76 cases together, the mean “near” peritumoural ADC was 2028.4 x 10-
6
mm
2
/s which did not differ significantly from the mean “far” peritumoural ADC of 
1994.9 x 10
-6
mm
2
/s. There was no significant variation of either variable by primary 
cancer type on one-way ANOVA. There was also no significant differences in 
patient outcomes (overall survival, local recurrence) when the cohort was divided 
into two “high” and “low” groups by either near peritumoural ADC, far peritumoural 
ADC or near:far ADC ratio and actuarial survival analysis performed. 
When visually inspecting the ADC maps for the 76 cases, however, it appeared that 
for a minority of metastases, in particular those from melanoma primaries, diffusion 
did vary greatly between the near and far peritumoural regions. The values of ADC 
at each point going out from the tumour towards normal white matter were plotted to 
give the “ADC signature” for that type of metastasis and an example of this is 
illustrated in Figure 3.9. It was relevant to directly compare such patterns of ADC 
change in two types of cancer known to show differing mechanisms of brain 
invasion, as discussed. The ratio of the near and far ADC values were therefore 
calculated for metastases of melanoma and non-small cell lung cancer and it was 
seen that for melanoma metastases this ratio was significantly higher (independent 2-
tailed t test = 2.259, df 36, p = 0.03).  
 
3.2.4.6 Multivariate analysis 
A Cox regression model was generated using the radiological and non-radiological 
factors found to be significant discriminators of overall survival in univariate 
analysis. Only post-operative WBRT (hazard ratio 3.1, 95% CI 1.5 – 6.8, p =0.004) 
and low ATC (hazard ratio 0.54, 95% CI 0.3 – 0.97, p=0.04) were found to be 
significantly associated with prolonged overall survival in this series. Multivariate 
analysis was attempted for progression free survival however modelling was 
inaccurate with large errors due to the high proportion of censored data (only 24% of 
the group or 16 cases developed local recurrence, as stated).  
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Figure 3.9: Changes in diffusion around a brain metastasis. A typical metastasis is shown in 
(A) with a clear boundary, necrotic centre and surrounding oedema, visible on the T2 
sequence. What is happening in the region around the metastasis? There is substantial 
evidence that this region consists of vasogenic oedema, higher diffusion and lower perfusion 
when compared to high grade glioma for example, but what about comparing within a group 
of metastases. (B). One can place serial regions of interest and measure and plot the ADC 
changes from the necrotic centre of the tumour through the leading edge and into the 
peritumoural regions.  (C) Box and whisker plots showing the median, interquartile range and 
outliers for ADC readings in and around melanoma (n=5) and non-small cell lung cancer 
(n=36) metastases demonstrates differences in this ADC signature between the two groups 
and within them but the biological correlate of these differences needs to be investigated. 
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3.2.5 Conclusions  
3.2.5.1 The value of tumor ADC in cerebral metastases 
This is the largest examination of diffusion weighted MRI and cerebral metastases to 
date. The numerical values for tumor ADC are in line with previous investigations of 
cerebral metastases which would be expected given the standard methods and 
protocols used for imaging and analysis (Berghoff et al., 2013c, Byrnes et al., 2011, 
Calli et al., 2006, Chen et al., 2012b, Chiang et al., 2004, Stadnik et al., 2001, Wang 
et al., 2009). We used a variety of methods of taking measurements from the ADC 
maps so as not to miss an effect due to our measurement technique. We have 
confirmed that ADC varies between cerebral metastases from different primary 
cancers but like others not sufficiently to distinguish the individual primary cancer 
type (Duygulu et al., 2010, Hayashida et al., 2006). This may be because the ADC 
reflects more general characteristics like cellularity. In support of this, ADC values 
were lower for the group of poorly differentiated metastases of melanoma and small 
cell lung cancer compared to the group of metastases from carcinomas (including 
breast and colorectal). We also corroborate the suggestion that tumor cellularity is 
inversely related to tumor ADC for a sample of our cases where tissue was available, 
whether measured by the minimum or the mean ADC. This is logical as more 
densely packed cells would broadly be expected to restrict diffusion, with the caveat 
that this coarse method of calculating ADC maps does not reflect the more subtle 
distinctions between intra and extracellular diffusion that others have derived using 
more advanced models in animals (Iima et al., 2014, Panagiotaki et al., 2014). 
However it has also been shown in cerebral metastases post mortem that a dense 
extracellular matrix correlates with low ADC, similarly suggesting a role for the 
tumor-stroma interaction we discuss later (Berghoff et al., 2013c). 
 
Our survival analyses generally support the finding of this smaller study (Berghoff et 
al., 2013c) that the pre-operative mean ADC of a cerebral metastasis is correlated 
with subsequent overall patient survival and we have now demonstrated this for a 
single tissue type; non-small cell lung carcinoma. We did not find that this effect 
persists in multivariate analysis. This may be due to including oligometastatic 
disease but it seemed reasonable to include such cases as they all had a single larger, 
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dominant lesion and we included the number of lesions as a confounding factor as it 
is included in the GPA score. These findings that ADC predicts prognosis are in 
keeping with a number of reports from other brain tumors where DWI has been 
applied to predict stage and prognosis (Porto et al., 2013, Mahmoud et al., 2011, 
Barajas et al., 2010) as well as other organ systems such as renal, rectal head and 
neck or cervical tumors (Somoye et al., 2012, Frankel et al., 2012, Squillaci et al., 
2004, Lambregts et al., 2011a, Matoba et al., 2013). In our series, in addition to 
whole brain radiotherapy - which is a treatment – it was only the change in diffusion 
across the tumour boundary which we call the ADC transition coefficient (ATC) that 
independently predicted the overall survival in multivariate analysis despite all other 
clinical factors. Why should this be? 
 
3.2.5.2 The brain-metastasis interface 
We have shown that changes in ADC across the brain-metastasis interface can be 
used to define the “sharpness” of this boundary, yielding additional information 
compared to assessing the boundary on T1 weighted contrast enhanced sequences 
alone. Rather than a low ATC and diffuse boundary on ADC map being associated 
with poor survival, as one might expect if this simply represented a more infiltrative 
pattern of growth, the reverse was true. A high ATC may in fact reflect high 
cellularity at the leading edge of the metastasis and hence greater tendency to recur. 
In support of this, the ATC was strongly linearly related to tumor cellularity in a 
sample of cases where tissue was available. One might predict that these cases may 
benefit from more aggressive local adjuvant treatments, such as wider surgical 
margins or radiosurgery “boost” to the cavity. Previous work on the interface 
between cerebral metastases and the surrounding brain has been conducted using 
histological methods on surgically resected or post mortem specimens (Raore et al., 
2011, Baumert et al., 2006, Neves et al., 2001) and this has certainly suggested that 
there are different patterns and depths of invasion, even if this has not been related to 
clinical outcomes. Furthermore, it has been shown that wider resection margins may 
improve clinical survival (Patel et al., 2010) and that ADC changes across the border 
of another brain tumor - oligodendroglioma - may predict growth pattern and 
aggressiveness.(Jenkinson et al., 2007)  Novel therapies acting at the brain-metastasis 
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interface are being developed (Goodman and Picard, 2012), therefore more accurate 
non-invasive, radiological methods may be needed to assess the degree of invasion of 
cerebral metastases and characterise the tumor boundary changes seen at diffusion 
MRI. 
 
3.2.5.3 The peritumoural region 
The MRI characteristics of the peritumoural region of cerebral metastases have 
previously been examined only in order to distinguish these tumors from glioma and 
abscess.(Sternberg et al., 2013, Mills et al., 2012, Price and Gillard, 2011) In this 
context the contrast enhancing margin has been taken as the reference and the near 
peritumoural region has been taken as being within 1cm of this edge. We have shown 
that for some metastases the ADC varies considerably from the core of the tumor, 
toward the leading edge and out into both the near and far peritumoural regions. It is 
known that the degree of T2 oedema may be a prognostic factor (Spanberger et al., 
2013a) and the different peritumoural ADC values in different metastases may be 
due to differences in the intensity of peritumoural oedema and/or underlying vascular 
permeability due to different patterns of infiltration. Melanoma metastases, for 
example, showed a significantly higher near:far peritumoural ADC ratio than non-
small cell lung cancer metastases in this study. These tumors are known to show 
different patterns of growth (Kienast et al., 2010), melanoma metastases co-opt 
existing vessels whereas lung adenocarcinoma stimulates neoangiogenesis and the 
pattern of peritumoural ADC changes might reflect this. In animal models suggest 
peritumoural ADC changes appear before T1 weighted gadolinium enhancement as 
micrometastasis formation and multiplication occurs (Serres et al., 2014). Tissue 
samples with paired radiological data would be needed to confirm what the correlate 
of these ADC changes are in humans, however it is unlikely that one would be 
practically able to gather tissue from deep within the region of peritumoural oedema 
around a metastasis as has been done for glioma (Kelly et al., 1987). The brain-
metastasis boundary is therefore a more fruitful area to investigate in the first 
instance. What are the biological differences in pattern of infiltration, vascularity, 
protein expression, inflammatory response in and around metastases with a sharp 
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versus a diffuse ADC border and therefore could the ATC or similar measures of 
diffusion change be used as a surrogate of such biological activity. 
 
3.2.5.4 Directions & limitations 
Image guided tissue specimens with matched radiological regions of interest are 
needed within and around cerebral metastases (as has been done with glioma) in 
order to confirm the underlying biological changes which account for the ADC 
patterns seen. This was a retrospective study, tissue was not universally available and 
was in paraffin embedded blocks from non-specific areas of the tumor, hence such an 
analysis was not possible. This study only examined ADC maps as more gradient 
directions were not available (again due to the MRI data having already been 
acquired and the analysis being retrospective) but ideally, more MRI sequences 
would be analysed pre-operatively including tractography and perfusion to allow a 
number of radiological metrics to be examined in and around metastases. These 
findings are also cautioned by the need for validated, reproducible methods of 
measuring DWI metrics. In particular, we found differences in “tumor ADC” 
between measuring whole tumor values, minimum values and taking the mean of 
multiple ROIs. A logical step would be to validate these metrics – in particular the 
ATC - on a separate dataset or series of cases with data gathered independently by 
another group and compare to conventional predictive models such as RPA and 
GPA. Different MR protocols have had to be combined in this series due to a need 
for large enough numbers for survival analysis. Again, data gathered in a prospective 
fashion on a single scanner with uniform protocols would be preferable. However the 
variations in T1 weighted contrast enhanced sequences (used as the reference for the 
tumor border) ought to be offset by the relatively hard boundary seen in these 
sequences and we have previously described good inter and intra-observer agreement 
measuring ADC metrics in brain metastases on different platforms. The prevalence 
of intratumoral haemorrhage in many brain metastasis types is a problem and reduces 
the number of cases which are suitable for analysis (cases with overwhelming 
haemorrhage were excluded as stated in the Methods) as well as potentially making 
these findings less relevant to cases which tend to bleed such as melanoma and renal. 
Nonetheless a reasonable spread of common histological types was used here. Newer 
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systemic therapies for treating cerebral metastases may lead to significant differences 
in survival between different tumor types and comprehensive clinical data with large 
numbers would be needed to stratify cases in future, for example by HER2 
responsiveness in breast carcinoma metastases. This makes large scale biomarker 
studies practically difficult and the need for collaboration between centres 
paramount. 
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Chapter 4: Combined in vivo analysis of the brain-brain metastasis 
boundary using advanced MRI and image guided sampling 
 
4.1 Introduction 
There are strong reasons for investigating the interface between the brain and the 
brain metastasis (B-BM interface) as a potential source of therapeutic opportunities 
and biomarkers. First, it has recently been shown that, far from being discrete, 
encapsulated tumours, brain metastases show a variety of growth patterns at the 
leading edge, with implications for prognosis (Siam et al., 2015) and treatment 
(Winkler, 2015, Berghoff et al., 2013b, Kienast et al., 2010). Second, the B-BM 
interface is the region in which the tumour interacts with the host immune system 
(Berghoff et al., 2013a, Puhalla et al., 2015, Hamilton and Sibson, 2013). Third, 
there are new therapies in each modality which act at the B-BM interface: cavity 
boost radiosurgery (Roberge et al., 2012), immune modulating drugs (Kluger et al., 
2015, Sugihara et al., 2009, Jones et al., 2015), and supra-marginal or en bloc 
surgical resection (Yoo et al., 2009, Patel et al., 2010). 
MRI provides a modality to assess the B-BM interface non-invasively, and could 
deliver biomarkers that apply to both resected and non-resected tumours. Advanced 
MRI and, in particular, diffusion MRI appears to be more sensitive at detecting 
changes in this region, on both the tumour and the brain side, earlier than other 
modalities (Serres et al., 2014, O'Connor et al., 2015, Mills et al., 2012). In addition 
to isotropic diffusion, it will be important to examine changes in anisotropic 
diffusion, as disruption of white matter tracts may be a sensitive marker of local 
tumour invasion (as it is in glioma) or other peritumoural changes, such as 
inflammation or neoangiogenesis. 
The final experiment in this thesis was therefore to perform image-guided 
neurosurgical sampling of the B-BM interface to assess MRI features (conventional, 
DWI and DTI), cellularity, growth pattern, cell division and host inflammatory 
responses for metastases from different primary cancers. 
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4.2 Methods 
4.2.1 Patients & follow up 
Overall 26 patients were studied prospectively and the clinical details are 
summarised in Table 4.1. All patients were undergoing complete resection of a 
supratentorial metastasis in the course of routine clinical care at a single institution. 
All patients had received dexamethasone 16mg per day in divided doses for at least 
72 hours prior to surgery. Performance status was assessed by clinicians at 
presentation.  
 
Table 4.1: Clinical details of brain metastases patients studied prospectively 
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Post-operative clinical course and oncology care, especially administration of whole 
brain radiotherapy (WBRT) or the use of adjuvant systemic chemotherapy (including 
targeted agents such as Herceptin©) were recorded from tumour board and patient 
notes prospectively, since these were potential confounding factors. Intracranial 
progression was determined by a neuro-radiologist as per the RANO criteria (Lin et 
al., 2015) in combination with the clinical findings, and all patients were discussed at 
the weekly tumour board / multidisciplinary team meeting. 
 
4.2.2 Image-guided sampling 
ADC maps and structural sequences were fused on the StealthStation S7 planning 
software (Medtronic Inc., MN, USA) and exported to an intraoperative workstation 
(Figure 4.1). The fused ADC sequence displayed as a colour map was used to avoid 
areas of cyst, necrosis which would not have been visible on the standard post-
contrast T1 weighted sequence alone, and the change in ADC was an indicator of 
cellular tumour “leading edge” transition to surrounding vasogenic oedema, with the 
latter having a very high ADC (Zakaria and Jenkinson, 2014d). 
 
Figure 4.1: Intraoperative screenshot of the fused ADC map (displayed as a colour image 
with high ADC in blue and low ADC in yellow) and inset, the Suretrak© probe attached to a 
biopsy forceps for use with the StealthStation S7©. 
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Using these fused sequences, samples were taken using the Suretrak© probe 
mounted on biopsy forceps. This technique allowed excellent specimens to be taken, 
demonstrating the transition from tumour to surrounding brain. For each case, an 
edge location was chosen which showed a radiological and histological interface 
with brain. The vector specifying the location of this sample (“edge”), along with one 
from the tumour interior (“core”) were extracted from the image-guidance software 
post-operatively (StealthStation S7, Medtronic Inc., MN, USA) and transferred to the 
offline image analysis software described below. Each location was double checked 
visually with screenshots taken in three orthogonal planes at each biopsy location 
during surgery. Regions of interest placed at this location, which was therefore co-
localised to the tissue sample taken intra-operatively, could then be applied to any 
parametric maps generated. This is illustrated in Figure 4.2. 
 
4.2.3 MRI studies 
At a median of 5 days prior to surgery, patients underwent an MRI brain scan. 
Sequences were requested by the managing clinician and protocoled by a clinical 
neuro-radiologist; for diagnosis T2 and unenhanced T1 sequences were acquired 
using standard parameters. For diagnosis and neuro-navigation, a volumetric fast 
spoiled gradient echo sequence was taken after gadolinium injection at a standard 
dose of 0.1mmol/kg (repetition time/echo time 9/1.4ms, flip angle 15 degrees, 
acquisition matrix 256×256, volume 180 × 1 mm slices at zero angle gantry); this is 
referred to as the planning scan. In 11/26 cases DWI with single-shot echo planar 
imaging at b values of 0 and 1000 second/mm
2
 was obtained and in 15/26 patients a 
DTI sequence (General Electric, 5 cases and Philips medical systems, 10 cases) 
enabling FA and MD maps to be generated. Philips scanner parameters were: 
Achieva 3.0T scanner with proprietary head coil, spin echo “DwiSE” sequence, total 
acquisition time 44.7 min, repetition time/echo time 2828/73 ms, field of view 
230x230mm, acquired matrix 128x128, slice thickness 4mm, 27 slice per volume, 
one volume without diffusion weighting (b=0 s/mm
2
) followed by 32 diffusion 
sensitised images with gradients applied in non-collinear directions (b=1000 s/mm
2
). 
GE scanner parameters were: Discovery MR750 3.0T scanner with proprietary head 
coil. Total acquisition time 40.3 min, repetition time/echo time 8000/87.8ms, field of 
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view 240x240mm, acquired matrix 128x128, slice thickness 4mm, 37 slices per 
volume, one volume without diffusion weighting (b=0 s/mm
2
) followed by  25 
diffusion sensitised images with gradients applied in non-collinear directions 
(b=1000 s/mm
2
). There was no difference in any ADC, MD, FA metrics from 
tumour, peritumoural regions or white matter by scanner vendor (independent 
median samples test p>0.05 for all comparisons), and it has been recently confirmed 
that the parameters being measured have good inter-scanner reproducibility (Grech-
Sollars et al., 2015).  
 
 
4.2.4 Image analysis 
The planning scan was reviewed by a neuro-radiologist blind to the clinical or 
histological data to assess the number and size of metastases as per recognised 
clinical criteria (Quant and Wen, 2011, Lin et al., 2015) as well as the degree of 
oedema on T2 weighted MRI using a previously defined scale (Spanberger et al., 
2013a). Additionally, contour segmentation software (ITK-SNAP version 3.0 
(Yushkevich et al., 2006)) was used to delineate the contrast-enhancing tumour and 
measure its volume.  
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Figure 4.2: A colorectal cancer brain metastasis removed for histological diagnosis and to 
relieve mass effect. An image-guided sample is taken intra-operatively and marked on the 
neuronavigation software (A). These coordinates are extracted and applied to the processed 
images after co-registration with the planning scan used in theatre, here the FA map is 
shown (B). Regions of interest are placed at the tissue sample location on both the tumour 
(edge) side and peritumoural side of the B-BM interface. The whole tumour is also 
demarcated using the contrast-enhancing margin and segmentation software. Whereas 
normally the whole, heterogeneous tumour (C, H&E stain) is analysed by MRI, now one can 
examine samples from the specific MRI location in (A) and see both the peritumoural and 
tumour characteristics that correlated with the MRI changes in these regions, here (D) on a 
section stained for GFAP (brown), the focal glial reaction to the tumour (blue) is shown. 
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For diffusion sequences, raw DICOM data was imported into DTIstudio, version 
3.0.3 (Jiang et al., 2006) with additional use of the ROIeditor module, version 1.7 
and MRIcron, version 6.6 (Rorden and Brett, 2000) as needed. Using the default 
settings (affine linear transformation, tri-linear interpolation, standard deriation of the 
ratio image) realignment and co-registration to b0 images was performed to remove 
eddy current distortions and quality control of baseline images was also checked 
visually. Tensors were calculated using standard linear regression and brain masking 
applied, inspecting the mask and correcting manually if required. An ADC trace map 
from DWI and, if more directions were available, the equivalent (Prah et al., 2014) 
mean diffusivity (MD) map from DTI were then generated. 2D fractional anisotropy 
(FA) maps were generated from tensors. Readings of average and minimum FA, 
MD/ADC were taken on the tumour and the peritumoural side of the location at the 
B-BM interface where the tissue sample was from as shown in Figure 4.2. The 
change in ADC/MD across the B-BM interface at the same location (the ADC 
transition coefficient or ATC) was calculated as previously described (Zakaria et al., 
2014c). Control readings were taken from the contralateral white matter by flipping 
the ROIs across the anatomical midline within the software, having double checked 
visually that this avoided any confounding structures such as ventricles or bone. 
Reduced FA indicates white matter tract disruption (anisotropic diffusion), whereas 
reduced ADC or MD represents restriction of diffusion in any direction (isotropic 
diffusion). 
 
4.2.5 Tissue analysis 
Histological assessment by a neuropathologist blind to MRI and clinical outcome 
was performed in the course of routine care to determine the primary cancer of origin 
and confirm the diagnosis. There were no misdiagnoses (e.g. pre-operative lesion 
operated as metastasis then found to be high grade glioma or lymphoma) and no 
lesions were excluded from analysis due to excessive haemorrhage (previously 
(Zakaria et al., 2014a) defined as >50% of the lesion being haemorrhagic at MRI or 
if haemorrhage precluded tissue analysis when IHC was performed). Primary cancer 
types are listed in Table 4.1. 
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4.2.5.1 Assessment of growth pattern at B-BM interface 
In the course of resection, the operating neurosurgeon gave a subjective assessment 
from microsurgical dissection of whether the tumour was well demarcated from the 
surrounding brain or not (henceforth termed the macroscopic assessment). A single 
neuropathologist was asked following completion of clinical care to categorise the 
growth pattern of all cases blind to the other MRI and immunological stains. They 
undertook this categorisation using a previously described system as either 
encapsulated, perivascular invasion or diffuse invasion (Berghoff et al., 2013b). All 
cases were then re-assessed by an independent observer for evidence of local 
invasion and any disagreements resolved (henceforth termed the microscopic 
assessment).  
 
4.2.5.2 Immunohistochemistry at B-BM interface  
Samples were taken using biopsy forceps (Figure 4.3) yielding specimens 
approximately 4x 3x 2mm. Samples were marked with a dot of black medical ink in 
theatre to show the deep pole, then stored in formalin for up to 24 hours before being 
placed into paraffin blocks with their orientation preserved, such that serial sections 
would not bisect tumour and adjacent brain (illustrated in Figure 4.4). Sections of 5 
micron thickness were cut and staining with haematoxylin & eosin (H&E) 
performed.  
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Figure 4.3: Biopsy forceps A. and in use on a model skull B. showing the size and 
planes available in 3 dimensions when taking intraoperative specimens.  
 
Figure 4.4: Illustration of specimen handling. A. The sausage shaped biopsy specimen taken 
from the leading edge of the brain metastasis (dark brown circle) was marked with medical 
ink (B) in theatre to denote the “brain” as opposed to the tumour pole. C. This mark was 
used in the laboratory to orient the specimen in the cassette to embed in paraffin, so that 
subsequent sections, taken along the plane marked with the scissors, gave an even 
distribution of tumour and peritumoural regions in each slide, seen in D. Other orientations 
produce serial sections at varying points across and even through the brain-brain metastasis 
interface, such as in E. where most slides contain only tumour and others only peritumoural 
white matter. 
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Table 4.2: Stains used to assess image-guided samples from tumour edge and core. 
Marker Function Antibody / stain Dilution Antigen 
retrieval 
CD34 
Endothelial antibody used to assess 
vascularity (Ramani et al., 1990) 
Mouse monoclonal 
#M7165 
Dako 
1:25 
EnVmse 
Proteinase 
K 
GFAP 
Filament protein found in astrocytes 
and used to assess reactive gliosis 
(Frank et al., 1986) 
Rabbit polyclonal 
#Z0334 
Dako 
1:1500 
EnVrbt 
Proteinase 
K 
CD20 
B cell differentiation antigen (Reinherz 
et al., 1986b) 
Mouse monoclonal 
#M0755 
Dako 
1:300 
EnVmse 
Citrate 
buffer (pH6) 
CD68 
Receptor involved in phagocytosis and 
expressed on macrophages (Micklem 
et al., 1989) 
Mouse monoclonal 
#M0814 
Dako 
1:100 
EnVmse 
Citrate 
buffer (pH6) 
CD3 
Non-specific T cell marker (Reinherz et 
al., 1986a) 
Rabbit polyclonal 
#A0452 
Dako 
1:50 
EnVrbt 
Tris-EDTA 
buffer (pH9) 
Reticulin 
Component of extra-cellular matrix 
(Bolonyi, 1958) 
(Gordon and 
Sweets, 1936) 
  
S100A4 
Calcium binding protein shown to 
promote metastasis in several animal 
models (Gross et al., 2014); over-
expression associated with intracranial 
progression in brain metastases 
Rabbit polyclonal 
#A5114 
Dako 
1:400 
EnVrbt 
none 
OPN 
Varied role in cell-matrix interaction, 
binds the cell surface integrins 
αVβ3/αVβ5 and promotes metastases 
(Anborgh et al., 2010, Hahnel et al., 
2010, Guttler et al., 2013). May be 
involved in radiation response in 
human brain metastases. 
Mouse monoclonal 
#MP111B10(1)  
Developmental 
Studies Hybridoma 
Bank(DSHB) 
1:300 
EnVmse 
none 
S100P 
Calcium binding protein inducing 
metastasis in breast cancer animal 
models (Wang et al., 2006). 
Mouse monoclonal 
#610307 
BD Biosciences 
1:75 
EnVmse 
none 
AGR2 
Normal component of ER highly 
overexpressed in range of human 
cancers. (Barraclough et al., 2009). 
Rabbit polyclonal 
#ARP42290 
Aviva Systems 
Biology 
1:750 
EnVrbt 
none 
MMP2 Matrix metalloproteinases are zinc- 
dependent, secreted endopeptidases 
essential for degradation and 
remodelling of the extracellular matrix. 
They are highly implicated in 
metastasis to and survival of cancer 
cells in the brain.(Vandenbroucke and 
Libert, 2014, Cathcart et al., 2015) 
Mouse monoclonal 
#MAB13431 
Chemicon 
1:40 
EnVmse 
none 
MMP9 
Rabbit monoclonal 
#ab137867 
Abcam 
1:100 
EnVrbt 
none 
MMP13 
Mouse monoclonal 
#MA5-14238 
Thermo Scientific 
1:60 
EnVmse 
none 
Ki67 
Marker of proliferation  
(Plate et al., 1990) 
Mouse monoclonal 
#M7240 
Dako 
1:75 
EnVmse 
Tris-EDTA 
buffer (pH9) 
NB: EnVrbt /EnVmse refers to the method used following primary antibody incubation:  
Dako Envision+ System-HRP (#K4011 for rabbit or #K4007 for mouse primaries). 
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Additionally, a number of other proteins acting as markers of proliferation, glial 
cells, inflammatory cells, connective tissue, ECM adhesion/remodelling and 
metastasis were examined and these are listed with details in Table 4.2. Stained 
slides were scored using a well described (Rudland et al., 2000) semi-quantitative 
method for the percentage and intensity of staining by two separate observers and the 
results compared to resolve any discrepancy. Lymphocytes and macrophages were 
manually counted (Rasheed Zakaria & Angela Platt-Higgins) up to a maximum of 
100 per high powered field (HPF, = 400x magnification) in as many fields as 
possible in the core and the edge samples (tumour infiltrating cells were defined as 
those in contact with cancer cells) as well as in the peritumoural region (defined as 
<1 high powered field of the tumour boundary on the edge sample) and distant white 
matter (>2 high powered fields from tumour edge). Cell counts were highly 
consistent between observers at intra-class correlation coefficient testing (Cronbach’s 
alpha=0.762, p<0.001). For Ki67, GFAP and connective tissue density, automated 
analysis with NIH ImageJ software was performed; version 1.49t (Schneider et al., 
2012) running in a 64-bit Windows environment using previously validated plugins 
e.g. (Tuominen et al., 2010). Slide photographs were taken using a Leica DFC310FX 
camera attached to a DM2000 microscope with the LAS V3 software suite (Leica 
microsystems, 2014) with no additional filtering. Images were stored using an 
uncompressed image file format (bitmap). For every imaging session, an image from 
an empty area of slide background was acquired (the blankfield image), which was 
used to correct for image colour balance and uneven illumination. 
 
4.2.6 Statistical methods 
Overall survival (OS) was taken as time from surgery to death and non-cancer deaths 
or those lost to follow up censored at last recorded follow up. Patients who died 
before progression were censored at the last date of follow up imaging. Proportions 
were assessed using Fisher’s two-sided exact test. Time-to-event comparisons were 
made using the Kaplan-Meier method with Log Rank tests and multivariate analyses 
conducted using Cox’s method. Correlations were assessed using Spearman’s rank 
test and pairwise comparisons using Wilcoxon’s signed rank test. Significance levels 
are generally stated, but were taken as p<0.01 if not given. Data processing was 
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performed using SPSS version 22.0 (IBM, Chicago, IL) and R version 3.10 (R Core 
Team, 2013). 
 
4.3 Results 
4.3.1 Clinical features  
Post-operative CT brain within 24 hours confirmed complete contrast enhancing 
lesion resection in all cases and there were no post-operative complications such as 
infection or haematoma in this series. Patients were generally of good performance 
status with controlled disease, as expected in a surgical cohort. Median overall 
survival (OS) was 5.5 months (95% CI 4.2 – 6.8) with 4 censored cases. Adjuvant 
WBRT was the only feature associated with increased OS, of 6.53 months (95% CI: 
5.4-7.7) versus 2.73 months (95% CI: 1.8 -3.6) untreated (log rank 16.26, p<0.001). 
10 of 26 patients experienced intracranial progression after surgery (3 distant, 7 local 
– i.e. in or around the surgical cavity) and the median progression-free survival (PFS) 
was 7.2 months (95% CI 4.6 – 9.8). There were no associations of any clinical factor 
with PFS time or site of progression (distant brain versus cavity). 
 
4.3.2 Conventional MRI measures  
There were 22 truly solitary metastases and 4 with a dominant lesion with additional 
unmeasurable lesions, effectively considered solitary. RANO “longest measurable 
diameter” ranged from 10mm – 57mm (median 28mm). Median volume was 8.5 cm3 
(range 0.4 – 65cm3). All metastases showed peritumoural oedema on T2 weighted 
sequences and in most cases (22/26) this was moderate (>1cm from but not crossing 
the midline), but in one case was mild (<1cm), and in three more severe (crossing 
midline or causing midline shift). The number of metastases, volume of disease and 
degree of peritumoural oedema were not associated with outcomes, however, 
tumours > 30mm in their longest axis showed a significantly shorter OS (HR for 
death if smaller than 30mm = 0.28, CI 0.11-0.70, p=0.006) even when controlling for 
WBRT.  
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4.3.3 DWI measurements reflect intra-tumoural heterogeneity  
The mean ADC of the 26 metastases was 1128x10
-6
mm
2
/s when considering the 
whole tumour, but this varied considerably by region (analysis of variance, Kruskal-
Wallis test highly significant, p <0.001) with higher values of 1505x10
-6
mm
2
/s for 
the core locations but 1059x10
-6
mm
2
/s at the leading edge locations and 1.414x10
-
6
mm
2
/s in the peritumoural region. Core and edge MD readings for each metastasis 
were analysed in pairwise fashion and showed significant differences in distribution, 
illustrated in Figure 4.5 (related samples Wilcoxon-signed rank test = -4.286, 
p<0.001). There was no relationship of the ADC or MD readings - either of the 
whole tumours or in any of the specific regions - to primary tumour histology, 
clinical factors or clinical outcomes. 
 
Figure 4.5: MRI showing the location of core and edge regions of interest for measuring 
ADC. The ADC varies depending on the region of the tumour assessed and the 
histogram of values coded by location shows this intra-tumoural heterogeneity. Metrics 
which group the whole tumour together as a single region would effectively miss this 
heterogeneity. 
 
4.3.4 Lower peritumoural FA is associated with longer overall survival 
To assess the B-BM interface, the change in ADC from tumour edge out into 
peritumoural tissue (the ATC) was derived and found to be comparable to the 
previous, larger series (median = 0.2314); nonetheless there were no differences in 
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microscopic invasion, peritumoural inflammation or any other biological measure 
between those metastases with a lower versus a higher ATC and accordingly no 
association with overall survival (log rank statistic = 0.065, p=0.799) or with 
time/site of intracranial progression was found. 
 
The peritumoural region alone was therefore considered separately from the tumour 
readings. The average FA measured in both the metastases (median 0.1090, range 
0.073 - 0.263) and the peritumoural region (median 0.1400, range 0.050 - 0.220) 
were significantly lower than in unaffected, contralateral white matter (median 
0.1980, range 0.103 – 0.341) indicating disruption of white matter tracts in both 
regions (related samples Wilcoxon-signed rank test for both comparisons, p<0.001). 
The peritumoural FA, but not the tumour FA, was strongly associated with overall 
survival in this surgical cohort. Figure 4.6 demonstrates that cases with a lower 
peritumoural FA, indicating more disruption of white matter tracts, showed longer 
survival times (median 9.9 months, 95% CI: 7.4-12.4 versus 5.3 months, 95% CI: 3.4 
– 7.13), even if tumour size and adjuvant WBRT were taken into consideration (in 
proportional hazards multivariate model, HR for death in lower peritumoural FA 
cases was 0.07, p=0.036). This result is counterintuitive, because in glioma studies 
variation in anisotropic diffusion is said to indicate tumour infiltrating and disrupting 
white matter tracts (White et al., 2011, Lu et al., 2004), whereas this would not be 
expected of BMs. Thus matched samples from the tumour and brain side at the same 
locations were examined to determine what the biological cause for increased 
survival and reduced anisotropic diffusion in these cases might be. 
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Figure 4.6: A. A lung adenocarcinoma brain metastasis which shows little peritumoural white 
matter disruption and has a high peritumoural fractional anisotropy (FA) value at the biopsy 
location shown. B. H&E, C. CD3 stained serial section showing sparse T cell infiltration in 
this same region (inset, magnified). This contrasts with the breast cancer brain metastasis in 
D, where there is more change in the peritumoural white matter and the FA value in the 
peritumoural region shown is lower. Here, there is dense peritumoural T cell infiltration (E, F 
and inset, magnified). G. The cases with a peritumoural FA >median (n=8, thick line) died 
sooner after neurosurgical resection of their metastasis than those with a lower peritumoural 
FA (n=9, dashed line) (log rank statistic = 4.566, p<0.05). H. The FA values differentiated 
categories of peritumoural CD3+ T cell density (<5, 5-25 and >25 per high power field) in the 
co-localised image-guided biopsy regions (Kruskal-Wallis, p<0.05), although such a relation 
is not seen with other immune cells such as CD68+ macrophages or CD20+ B cells nor is it 
seen with other MRI measures, such as the mean diffusivity (MD).  
FA (8) 
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4.3.5 The leading edge is a distinct biological region but this does not explain the 
variation in peritumoural FA  
The intra-tumoural heterogeneity seen at DWI was mirrored when examining tissue 
samples. The paired samples from edge and core locations indicated lower necrosis 
(Wilcoxon paired samples test -2.921, p=0.03) and higher vascularity (CD34+ 
vessels, 1.98, p=0.048) in the leading edge over the core. However, there was no 
significant difference in connective tissue density, proliferation (Ki67 index) or the 
expression of metastasis inducing proteins & matrix-metallo-proteinases between the 
regions. These results are summarised in Table 4.3.  
 
Table 4.3: Table comparing edge and core biologically for a number of different parameters. 
Parameter 
assessed: 
Core 
(units given) 
Leading edge 
(units given) 
Comparison of core vs. edge  
(test & significance given) 
Connective 
tissue 
(reticulin) 
density 
High = 22 cases 
Low = 4 cases 
High = 18 cases 
Low = 7 cases 
Fishers’ Exact test, p=0.3 
Proliferation 
(Ki67 index) 
28% (6 – 64) 21% (5 – 99) Wilcoxon matched pairs, p=0.637 
Necrosis 
30% of field 
(range 0 – 90) 
5% of field 
(range 0 – 50) 
Wilcoxon matched pairs, p=0.003* 
Vascularity  
1.9 CD34 + 
vessels per 
0.5mm
2
  
(range 0 – 11) 
4.9  CD34 + 
vessels per 
0.5mm
2
  
(range 0 – 33) 
Wilcoxon matched pairs, p=0.032* 
Protein: 
Core 
(% positive 
cells/sample) 
Core, 
proportion 
positive  
(1% cut-off) 
Leading edge 
(% positive 
cells/sample) 
Edge, 
proportion 
positive  
(1% cut-off) 
S100A4 70 19/24 (79%) 55 23/26 (88%) 
S100P 60 20/24 (83%) 60 20/26 (77%) 
AGR2 5 15/24 (63%) 5 18/26 (69%) 
OPN 45 21/24 (88%) 70 22/26 (85%) 
MMP2 43 17/24 (71%) 60 19/26 (73%) 
MMP9 55 22/24 (92%) 45 23/26 (88%) 
MMP13 20 15/24 (63%) 20 15/25 (60%) 
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There was a trend to increased positive staining for the protein S100A4 - which is 
associated with intracranial progression - at the leading edge versus the core. There 
were no differences in cellularity, proliferative index, vascularity, necrosis or 
connective tissue density in the tumour edges adjacent to peritumoural regions that 
had lower versus higher FA readings. 
 
4.3.6 Invasive growth patterns are poorly predicted macroscopically, but not 
associated with altered peritumoural FA or reduced survival 
Overall 118 samples were obtained from the 26 metastases with a median of 5 
samples per case. Microscopically 71/118 samples showed evidence of tumour cells 
beyond the apparent B-BM margin, whereas 20/26 cases were reported 
macroscopically by the operating neurosurgeon to have a clearly defined border to 
white matter; the kappa statistic (0.02) indicated the significant discordance of micro 
and macroscopic assessments, illustrated in Figure 4.7. There was no infiltration of 
tumour cells beyond one high powered field width or 0.5mm, from the apparent B-
BM margin. 
 
All the breast cancer metastases studied (4/4) showed diffusely infiltrating growth 
patterns microscopically, whereas lung cancers were less likely to have a surgical 
plane at operation (only 2/13 were encapsulated), however, overall there was no 
significant association of invasive growth with primary cancer histology (Fisher’s 
test = 2.166, p=0.939). Importantly, there was no relation of growth pattern to the 
subsequent survival (HR for death of an encapsulated metastasis = 0.73, 95% CI 0.42 
– 1.28, p=0.28). There was no association of growth pattern with the FA in the 
peritumoural region, whether classified by a pathologist microscopically (Kruskal-
Wallis test p=0.539) or a neurosurgeon macroscopically (Mann-Whitney U, p=1.0).  
 
 
R ZAKARIA - PHD THESIS: LOCAL INVASION IN CEREBRAL METASTASES                              -99-    
 
Figure 4.7: A. Macroscopic assessment by the operating neurosurgeon – defined as a clear 
plane found at microsurgical dissection – was discordant with the microscopic growth pattern 
observed in the laboratory using samples from the leading edge of the tumour. B. For 
example, in this breast cancer brain metastasis, the operating neurosurgeon recorded a 
complete macroscopic resection with a clear plane to surrounding brain in the operative 
notes (H&E stained specimen, 12.5x magnification). C. Microscopically, however, there was 
a diffusely invasive leading edge (H&E, 200x magnification). Neither the macroscopic nor the 
microscopic growth patterns seen at surgery were predictive of overall survival or time to 
intracranial progression. 
 
Peritumoural FA was not a surrogate of biological differences in the metastasis’ 
leading edge, such as cellularity or the expression of metastasis inducing proteins, 
and it was not a surrogate of a particular phenotype, such as diffusely invasive 
growth.  We therefore hypothesised that the peritumoural FA might be related to host 
response to the brain metastasis. 
 
 
4.3.7 T-cell infiltration at the B-BM interface is variable, associated with 
survival and reflected by peritumoural FA 
We consistently observed dense macrophage infiltration at the B-BM interface across 
tumours from different primaries (median 62 CD68-positive cells per HPF in 
peritumoural regions versus 21 per HPF in control regions, shown by primary cancer 
type in Figure 4.8). This peritumoural infiltration was also significantly greater than 
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in the core or the edge of the metastases (related samples Wilcoxon tests p<0.001 for 
all comparisons, cell counts shown in Table 4.4) and qualitatively we observed a 
wall of macrophages surrounding the tumour rather than islands or a diffuse infiltrate 
extending away from the tumour edge. Metastases were accompanied by a diffuse 
glial reaction in the adjacent brain (peritumoural GFAP-positive cell density was 
significantly greater than control white matter, related samples Wilcoxon test, 
p=0.003, see Stable 4.4), however only 5/26 tumours were noted to have the 
pseudocapsule of compressed glial material around them as reflected in the growth 
pattern assessment described earlier. There was some evidence of increased 
peritumoural vascularity (median 2 CD34-positive vessels per HPF, compared to <1 
in control regions, p=0.001) but this was not significantly different to the core or 
edge of the metastases (paired Wilcoxon tests p=0.57 and p=0.17 respectively, cell 
counts in Table 4.4). No difference was seen even when those tumours with a co-
opting growth pattern (4/26) - which would not be expected to rely on neo-
angiogenesis - were excluded. CD20-positive B cell infiltration was sparse (median 
<1 cells per HPF in the edge and peritumoural regions, no significant difference from 
control white matter, Table 4.4). 
 
 
 
Table 4.4: Inflammatory cell infiltration in different regions around brain metastases, 
expressed as median number of immunoreactive cells per high powered field (=0.5mm
2
) for 
each given stain, range in brackets. Spearman rank correlation test statistics are shown and 
asterisk highlights significant correlations.  
WM = white matter, HPF = high powered field. 
Parameter/ 
region 
Core 
Leading 
edge 
Peri- 
tumoural 
Control 
WM 
Edge vs. 
Core 
Peri-
tumoural 
vs. Edge 
Peri-
tumoural 
vs. 
Control 
Macrophage 
infiltration 
(CD68) 
19.0  
(5 – 108) 
20.3  
(0 – 110) 
62.3  
(9 – 320) 
20.5  
(3 - 72) 
0.67* 0.04 0.17 
B cell infiltration 
(CD20) 
0  
(0 - 10) 
0.2  
(0 - 37) 
0.1  
(0 - 5) 
0  
(0) 
0.73* 0.60* 0.58* 
T cell infiltration 
(CD3) 
4.1  
(0 – 95) 
10.1  
(0 - 195) 
16.3  
(0 - 113) 
1.4  
(0 - 15) 
0.73* 0.63* 0.39 
Glial reaction 
(GFAP+ cell 
density) 
  
41%  
(26 - 68) 
34%  
(16 - 45) 
  0.21 
Vascularity 
(CD34+ vessels 
per HPF) 
1.9 (0 -11) 3.1 (0 - 33) 2.2 (0 – 9) 0.4 (0 – 5) 0.30 -0.09 -0.03 
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CD3-positive lymphocytes, assumed to be T-cells, were seen in the peritumoural 
region in all except 1 case (median 16 cells per HPF, significantly greater than 
control white matter, p<0.001). A single patient with malignant melanoma was 
taking ipilimumab (an immune checkpoint inhibitor) prior to surgery and their brain 
metastasis demonstrated significantly higher peritumoural T-cell infiltration (Mann-
Whitney U statistic = 3.583, p<0.001) than the other three malignant melanoma 
metastases and a trend to higher macrophage infiltration (Mann-Whitney U statistic = 
2.049, p=0.056), both highlighted in Figure 4.8.  
 
 
Figure 4.8: The distribution of inflammatory cells in the peritumoural region expressed as 
number of immunoreactive cells per high powered field (0.5mm
2
) and categorised by primary 
cancer. Dashed lines show the group median number of each cell type. The dashed circle 
highlights a patient with malignant melanoma who had been receiving immune stimulating 
therapy (ipilimumab, a CTLA-4 blocking antibody). 
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Even when excluding this case, there was no significant variation in numbers of any 
type of immunoreactive cells in any region (core, edge or peritumoural) by primary 
cancer of origin for these brain metastases (Kruskal-Wallis tests p>0.05 for each 
comparison). Cancers with extracranial metastases had a significantly lower 
tumoural and peritumoural T-cell infiltration in the brain whereas synchronous cases 
showed significantly elevated numbers of immunoreactive cells compared to control 
white matter (Mann-Whitney U, p<0.05). No other clinical factors, such as the 
control of the primary disease, number or location of cranial metastases, patient age 
or gender had any significant association with immunoreactive cell counts.  
The different immune response in different metastases appears clinically relevant 
since peritumoural T cell infiltration, but not edge or core T cell infiltration and not 
peritumoural macrophage or B cell infiltration, was associated with prolonged OS, 
even when controlling for the confounders WBRT and tumour size by multivariate 
Cox regression analysis (illustrated in Figure 4.9A and Table 4.5). When the 
response was further categorised into 3 groups (<5, 5-25 and >25 median 
immunoreactive cells per high powered field), those with moderate peritumoural T 
cell infiltration appeared to be at no advantage compared to those with low 
infiltration, whereas those with the highest T cell infiltrates still maintained a 
survival advantage (Figure 4.9B). 
Figure 4.9: A. Higher than median peritumoural T cell count is associated with improved 
overall survival for resected brain metastases, compared to lower than median (log rank test 
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= 5.77, p = 0.016) and the highest counts are associated with longer overall survival 
compared to moderate and low counts (log rank = 10.06, p=0.007). 
 
 
HR for death 95% CI for HR Sig. 
Adjuvant WBRT 0.117 0.031 – 0.435 .001 
Longest axis > 30mm 3.226 1.190 – 8.748 .021 
Density of CD3+ cells in  
peritumoural region 
0.962 0.931 - 0.994 .021 
 
Table 4.5: Multivariate Cox proportional hazards model for overall survival.  
Since peritumoural FA was also associated with survival, and biologically white 
matter may be expected to be disrupted by lymphocyte infiltration, the co-localised 
MRI and tissue data were compared for these features. Only the peritumoural density 
of CD3+ T-cells differed between the high and low peritumoural FA regions (Mann 
Whitney U, p=0.037), as seen in Figure 4.6H. The continuous values for 
peritumoural CD3+ T-cell density and peritumoural FA were compared for co-
localised samples and were strongly correlated (Spearman’s rho, p=0.004), whereas 
MR features such as ADC, MD in that region, or FA in the tumour at that location, 
showed no such association. 
 
4.4 Discussion 
In this first-in-man examination of the relationship between advanced MRI 
measurements and inflammation at the B-BM interface, we have shown that the FA 
in the peritumoural region is significantly associated with the density of T cell 
infiltration there and that increased CD3+ T cell infiltration is associated with 
prolonged overall survival after macroscopic resection. This effect is independent of 
giving adjuvant WBRT or smaller tumour size, the only other factors significantly 
extending overall survival in this cohort. These novel findings highlight the role of 
the tumour microenvironment in mediating BM behaviour and suggests 
inflammatory responses in this region can be measured non-invasively in patients 
with different primary cancers in a clinically relevant context.  
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4.4.1 Advanced MRI findings at the B-BM interface 
The MRI characteristics of brain metastases have been extensively studied using 
DWI for isotropic and DTI for anisotropic diffusion (Zakaria et al., 2014b, Mills et 
al., 2012, Price et al., 2004). Numerical findings in this series are entirely in keeping 
with those previously recorded by ourselves and other groups (Zakaria et al., 2014a). 
Even those studies which focused on the B-BM interface by measuring changes in 
the peritumoural region, rather than just in the tumour, have exclusively examined 
tumour invasion (Price et al., 2004, Lu et al., 2004, Lemercier et al., 2014). The 
finding that brain metastases are only locally invasive to a small depth compared to 
glioma - also extensively characterised by advanced MRI – has led to a number of 
studies seeking to distinguish these two tumour types. In such schemes, the 
peritumoural FA is shown to be significantly less in glioma (i.e. white matter more 
disrupted), in keeping with the biological nature of this cancer, invading through and 
along white matter tracts e.g. (Price and Gillard, 2011, Byrnes et al., 2011, Kelly et 
al., 1987). There has been little or no attempt to look at the intra- and inter-tumoural 
heterogeneity for brain metastases (Duygulu et al., 2010, Hayashida et al., 2006). It 
may be that a focus on measuring the degree of tumour infiltration or invasion is 
missing an important biological effect. The brain is uniquely sensitive to 
inflammatory changes which disrupt white matter and this can be assessed by 
changes in anisotropic diffusion, as has been shown for large series of patients with a 
variety of pathologies including multiple sclerosis (Commowick et al., 2008), stroke 
(Jiang et al., 2010), dementia and head injury (Fakhran et al., 2013). Brain metastases 
offer a unique opportunity for investigation, since there is no diffuse invasion of 
tumour cells to disrupt the white matter signal being measured. MRI changes may 
appear with very little inflammatory response as the brain is a privileged 
environment and DTI is often obtained in the routine course of clinical assessment 
and surgical planning. 
Taken in concert with our previous work (Zakaria et al., 2014c), we suggest that ours 
and other previous studies assessing the B-BM interface may have been imaging 
immune response rather than tumour differences across the leading edge, and this has 
only become clear when MRI data in both regions along with matched tissue are 
analysed together. This analysis has been undertaken here for the first time in 
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patients with active disease as opposed to post mortem tissue (Berghoff et al., 2013a) 
or in animal models (Serres et al., 2014). 
 
4.4.2 The immune cell response at the B-BM interface varies between patients 
and is associated with prolonged survival 
Immune response and in particular quantifying tumour-associated CD3+ T cells is 
currently of great interest as a means of improving prognostication and developing 
therapies in cancer medicine (Gooden et al., 2011). A small number of reports have 
disagreed on the degree of T cell infiltration in brain metastases from solid organ 
cancers (Kluger et al., 2015, Berghoff et al., 2015). From our findings, this is not 
surprising, since there is a considerable variation in numbers of immune and 
inflammatory cells with location. Random tumour “cores” of the type obtained and 
used in high throughput studies may be missing the effects seen here, where larger 
samples have been taken in vivo from the B-BM interface. There is already post-
mortem data suggesting the presence of immune cells may be more pronounced at 
this location (Berghoff et al., 2015) and we have now shown measurable intra-
tumoural heterogeneity in brain metastases. We have also shown that in patients with 
brain metastases taking oral steroids at clinically meaningful doses, who have been 
treated with systemic chemotherapy, CD3+ T cells can be reliably detected in their 
brain metastases and their presence is associated with increased survival. In one case, 
a patient had been treated with immune stimulating therapy in the form of anti-
CTLA4 antibody (ipilimumab), which has been shown to improve metastatic brain 
disease in melanoma patients (Margolin et al., 2012). Demonstrating increased 
peritumoural T cell infiltration in such a patient compared to others with a similar 
tumour is important because it confirms that in a neurosurgical patient on 
chemotherapy and oral steroids, the cellular immune response around the tumour is 
still measurably increased. 
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4.4.3 Intra-tumoural and inter-tumoural heterogeneity did not predict survival 
in this series, but can be detected at MRI 
Recent studies have divided brain metastases of various primary cancers into more 
and less invasive phenotypes both in vivo (Neves et al., 2001, Siam et al., 2015) and 
post mortem (Berghoff et al., 2013b) and attempted to relate this invasive phenotype 
to primary cancer type and prognosis. These studies all recognise that whilst there 
may be varying degrees of invasion locally, metastases do not show the degree of 
deep, widespread tumour infiltration seen in glioma (Kelly et al., 1987) and,  indeed, 
some surgical studies have found the B-BM interface to be strongly demarcated 
(Baumert et al., 2006). We have confirmed that there is intra-tumoural heterogeneity 
in brain metastases with necrotic, fluid cores and more cellular leading edges. 
Further, we found inter-tumoural heterogeneity at these edges with varying patterns 
and degrees of local invasion which were not predicted by the operating surgeon’s 
assessment of the B-BM interface. Nonetheless, there were no significant differences 
found in the potential drivers of invasion, such as MMP, MIP expression nor in the 
downstream hallmarks of more aggressive tumours, such as high nuclear:cytoplasmic 
ratio, higher Ki67 index or increased vascularity. Purely descriptive studies are 
useful in increasing biological understanding, but the overriding clinical evidence on 
treatment of brain metastasis from many diverse trials suggests a more complex 
interaction between local (SRS, surgery) and whole brain treatments (WBRT) than 
could be explained simply by a binary classification of the B-BM interface as 
invasive or circumscribed. Genetic analysis of the tumour core and the edge, using 
RNA sequencing for example, or from edges of rapidly locally recurring cases versus 
the opposite, may deepen understanding about what underlies the observed 
differences on the tumour side, even if some changes on the brain side have already 
been described (Siam et al., 2015). 
 
4.4.4 Limitations and future directions 
It is important to note that the samples obtained in the course of this study are not 
routinely available, unless one is intentionally undertaking a supra marginal excision, 
as has been proposed by some neurosurgeons (Patel et al., 2010, Yoo et al., 2009). 
Normally one would obtain a core biopsy or piecemeal tumour specimens which are 
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sufficient for diagnosis and, increasingly, genetic analysis (Brastianos et al., 2015) 
but not for any peritumoural changes. This is why it is so important to have 
demonstrated a potential non-invasive surrogate marker of peritumoural T cell 
infiltration, since it offers the possibility of assaying the immune response even for 
inaccessible or non-surgical cases. 
 
The IHC techniques are intentionally simple so as to make clinical applicability as 
broad as possible. We need to apply more specific stains to serial sections from the 
leading edge locations in order to determine the type and activation of the T cells 
seen. It would also be of note to determine if potential modifiable drug targets such 
as PD-1 and PD-L1 are present in the adjacent tumour tissue, as this would offer 
further evidence for using existing drugs to modify the immune response. 
 
The image guidance system used here is of the sort routinely available in clinical 
neurosurgical practice in Europe and North America. The system is not designed or 
licensed for obtaining co-localised MRI and tissue data specifically, and the accuracy 
of this localisation is dependent on a number of factors ranging from the fidelity of 
the “planning” preoperative MRI scan to the type of image registration algorithms 
applied (Widmann et al., 2012). One could have improved this accuracy, feasibly, by 
using an instrument- or robot-mounted tool to take samples, as opposed to hand held 
forceps. Such tools would limit the freedom of movement and angle of sampling, 
reducing the surgeon’s ability to manoeuvre the probe to the true B-BM interface 
under direct visual and computer-aided navigation, as compared to taking needle 
biopsies from a closed cavity through a burr hole for example. To reflect this 
uncertainty we have used a 5mm diameter “region” of biopsy rather than a voxel-
sized point and have taken average readings across this region to mirror the median 
cell counts used to assay immune cell infiltration in a given area. Finally, in 
neuronavigation there is an issue of brain shift (Kuhnt et al., 2012) where the pre-
registered navigation is rendered inaccurate once CSF is released and, although one 
can try to correct for this shift using intraoperative ultrasound, this is not our routine 
clinical practice, since it requires intense computational power and incurs a time 
delay. This is of little practical benefit in navigation when dealing with mostly 
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superficial tumours (metastases are mostly seen at the grey-white matter zone), 
where the brain oedema balances the loss of CSF on opening the dura.  
 
Further study could be directed at using DTI to measure the response to immune 
therapy over time, e.g. during ipilimumab therapy in melanoma patients, or by 
matching T cell infiltration to further advanced imaging techniques such as perfusion 
and spectroscopy. These imaging techniques may be equally good surrogates for T 
cell infiltration in the peritumoural region. It would also be pertinent to use differing 
MR analysis tools, e.g. generating tracts and measuring the FA change along these 
where they overlap with a biopsy region.  
 
4.5 Conclusion 
We have tested the hypothesis that the immune reaction to brain metastases is 
variable and shown that the CD3+ T cell density in the peritumoural region is 
independently associated with overall survival for patients with an operated brain 
metastasis from solid organ cancer. Higher T cell infiltration in this region is 
associated with white matter disruption and a decrease in anisotropic diffusion as 
measured non-invasively by diffusion weighted MRI. 
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Chapter 5: Conclusions and future directions 
 
5.1 Summary of the clinical problem 
Brain metastases are an important clinical problem and there are a number of unmet 
needs that have been discussed in the course of this thesis. Despite a variety of 
scoring systems to predict patient survival, there are no individualised markers of 
overall survival or intracranial progression in brain metastases. Such markers would 
be useful because there is deep uncertainty about the best combination of local 
therapies (surgery, SRS) and whole brain radiotherapy in treating these tumours. 
Furthermore, there is limited understanding of the brain-brain metastasis (B-BM) 
interface, but early investigations have suggested a more complicated interaction 
between the tumour and host than had been assumed previously and certainly more 
complex than the macroscopic appearance suggests. This has implications for clinical 
management, since there is currently no diagnostic means to determine those 
tumours that are more invasive and would potentially benefit from more aggressive 
local treatments such as cavity boost radiation or wider surgical resection margins. 
The B-BM interface is also the focus of the host-tumour interaction, including the 
immune response and therefore a source of potential therapeutic targets. 
 
5.2 Summary of experimental findings in relation to original hypotheses 
The aim of this thesis was to derive biological and radiological markers of local brain 
metastasis invasion, intracranial progression and survival which may be used in 
clinical practice, whilst deepening scientific understanding of the brain-brain 
metastasis interface.  
 
The first hypothesis was that proteins which induce a metastatic phenotype in solid 
organ cancers are also involved in local invasion in brain metastases and that levels 
of expression of such proteins may be associated with clinical outcomes such as 
survival and progression for patients with brain metastases. I have shown that 
proteins known to be associated with metastasis in other cancers are also widely 
expressed in brain metastases, regardless of the primary cancer of origin. In 
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particular, the metastasis-inducing protein S100A4 was overexpressed in brain 
metastases that progressed after surgical removal, although there was insufficient 
detail in this retrospective series to determine if this was local or distant brain 
recurrence. Overexpression of the metastasis inducing protein osteopontin was 
associated with a survival benefit after WBRT.  These are potentially useful clinical 
markers because there is a trend to try and omit whole brain irradiation after surgery 
for these metastases. If used in combination, for example, patients with a resected 
metastasis expressing S100A4 and osteopontin might be stratified for treatment with 
adjuvant WBRT, rather than active surveillance, as they have a higher risk of 
progression and better radiation response.  
 
The second hypothesis was that measurements may be taken from diffusion weighted 
MRI brain scans of patients with brain metastases with high reliability on clinical 
grade hardware and software. This was well demonstrated and subsequent larger 
studies have repeatedly confirmed such findings across different pathologies and 
different MRI scanning facilities. Next we hypothesised that these MRI measures 
may be associated with clinical outcomes such as survival and progression in patients 
with brain metastases. Analysis of pre-operative MRI scans showed that the diffusion 
change across the B-BM boundary, rather than any diffusion characteristic of the 
metastasis itself, was independently associated with overall survival. A sharp change 
in ADC from tumour edge into peritumoural brain predicted worse survival. This 
was initially felt to be counterintuitive, as one would expect such cases to be more 
completely resected and show less local invasion at the leading edge. However, using 
unmatched tissue, we demonstrated that a sharp change in ADC reflected high 
leading edge cellularity and intense vasogenic oedema.  
 
The final hypothesis was that differences between tumours in diffusion weighted 
MRI characteristics at the B-BM boundary reflected underlying differences in 
invasive growth pattern, metastasis inducing protein expression and markers of 
aggressive behaviour such as vascularity, cellularity and proliferation. In fact, 
analysis of image-guided samples from the B-BM interface revealed that ADC 
changes at the leading edge were not indicative of local invasion or invasive growth 
patterns in this region, but instead found that there was variable infiltration of T cells 
in the peritumoural region. Those cases with a higher peritumoural T cell density 
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showed longer overall survival, even when controlling for other confounding 
variables and radiation treatment. Instead of detecting this change by isotropic 
diffusion on the ADC maps, we observed only changes in anisotropic diffusion, 
measured by the FA values and reflecting peritumoural white matter infiltration by 
these immune cells. In hindsight this is actually a very logical result, since we know 
that white matter is uniquely sensitive to changes in inflammation and immune 
infiltration from other more widely studied pathologies such as head injury and 
multiple sclerosis.   
 
5.3 Areas for further investigation 
The T cell findings provide a biological rationale for the recent emergence of 
immune therapy as a possible treatment in cancer and brain metastases. There are 
licensed drugs (such as ipilimumab) that enhance and deregulate the cellular immune 
response. Disease monitoring of brain metastasis response currently relies on 
contrast-enhanced margins on MRI. Our data suggest that diffusion MRI could be 
used to measure the immune cellular response (i.e. the host response) by determining 
the degree of peritumoural inflammation. Serial DTI data in a series of patients 
undergoing immune-modifying therapy is essential to investigate this further. One 
patient with melanoma in this series receiving ipilimumab showed an enhanced 
response and appropriate FA changes demonstrating proof of concept for disease 
monitoring. A future study in brain metastases, therefore, might be based on using 
DTI to stratify patients for immune modifying therapy. A number of clinical trial 
concepts also arise from this thesis. A randomised trial of cavity SRS versus 
observation versus WBRT has never been performed and one possibility is to stratify 
solitary metastases after resection using the markers OPN or S100A4 to observation 
if there is a low risk of intracranial progression as opposed to radiotherapy if there is 
a high risk. A surgical trial would be to randomise solitary metastases to either 
standard of care surgical resection or intentional “super marginal” resection where a 
cuff of normal appearing brain around the metastasis is also resected to include 
microscopic infiltrates with or without a local SRS boost to the cavity. This thesis 
has highlighted new approaches and possibilities that will inform the field and 
stimulate collaboration and hopefully progress for the unfortunate and increasing 
number of patients suffering with brain metastases. 
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